[INFO] POST /api/login 200 in 361ms
[INFO] GET /api/user 304 in 60ms
[INFO] GET / 200 in 63ms
[INFO] GET /api/podcasts 304 in 114ms
[INFO] GET / 200 in 75ms
[INFO] GET / 200 in 63ms
[INFO] GET /api/playlists 304 in 239ms
[INFO] 
========Streaming audio file: 1735651217703-article.mp3
[INFO] ========Range undefined
[INFO] HEAD /api/audio/stream/1735651217703-article.mp3 200 in 754ms
[INFO] 
========Streaming audio file: 1735651217703-article.mp3
[INFO] ========Range bytes=0-
[INFO] Stripe initialized successfully
[INFO] ***Starting server initialization...


[INFO] Registering routes...
[INFO] Setting up Vite for development...
[INFO] Server started successfully on port 4000
[INFO] Webhook endpoint available at: https://PodCasterella.VivekGopal1.repl.co/api/webhooks/stripe
[INFO] GET / 200 in 60ms
[INFO] GET /@vite/client 304 in 37ms
[INFO] GET /src/main.tsx 304 in 79ms
[INFO] GET /@react-refresh 304 in 56ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 1ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 426ms
[INFO] GET /src/lib/queryClient.ts 304 in 52ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 102ms
[INFO] Stripe initialized successfully
[INFO] ***Starting server initialization...


[INFO] Registering routes...
[INFO] Setting up Vite for development...
[INFO] Stripe initialized successfully
[INFO] ***Starting server initialization...


[INFO] Registering routes...
[INFO] Setting up Vite for development...
[INFO] Server started successfully on port 4000
[INFO] Webhook endpoint available at: https://PodCasterella.VivekGopal1.repl.co/api/webhooks/stripe
[INFO] GET / 200 in 45ms
[INFO] GET /@vite/client 304 in 66ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 1ms
[INFO] GET /src/main.tsx 304 in 132ms
[INFO] GET /@react-refresh 304 in 73ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 564ms
[INFO] GET /src/pages/AdminPage.tsx 200 in 2ms
[INFO] GET /src/hooks/use-user.ts 200 in 3ms
[INFO] GET /src/pages/AuthPage.tsx 200 in 3ms
[INFO] GET /src/pages/ProfilePage.tsx 200 in 1ms
[INFO] GET /src/components/Sidebar.tsx 200 in 1ms
[INFO] GET /src/components/ui/button.tsx 200 in 2ms
[INFO] GET /src/pages/BillingPage.tsx 200 in 2ms
[INFO] GET /src/pages/ForgotPasswordPage.tsx 200 in 1ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 1ms
[INFO] GET /src/lib/queryClient.ts 304 in 1ms
[INFO] GET /src/index.css 200 in 2494ms
[INFO] GET /src/pages/HomePage.tsx 304 in 1ms
[INFO] GET /src/pages/PricingPage.tsx 304 in 0ms
[INFO] GET /src/hooks/use-toast.ts 200 in 1ms
[INFO] GET /src/pages/LibraryPage.tsx 304 in 1ms
[INFO] GET /@fs/home/runner/PodCasterella/db/schema.ts 304 in 1ms
[INFO] GET /src/components/ui/input.tsx 304 in 1ms
[INFO] GET /src/components/ui/card.tsx 304 in 0ms
[INFO] GET /src/components/ui/form.tsx 304 in 2ms
[INFO] GET /src/components/ui/scroll-area.tsx 304 in 0ms
[INFO] GET /src/components/Logo.tsx 200 in 1ms
[INFO] GET /src/components/ui/tabs.tsx 304 in 0ms
[INFO] GET /src/lib/utils.ts 200 in 0ms
[INFO] GET /src/components/ui/avatar.tsx 304 in 1ms
[INFO] GET /src/components/LoadingScreen.tsx 304 in 1ms
[INFO] GET /src/components/PaymentModal.tsx 304 in 1ms
[INFO] GET /src/components/ui/separator.tsx 304 in 1ms
[INFO] GET /src/components/UsageProgress.tsx 200 in 2ms
[INFO] GET /src/components/ui/toast.tsx 200 in 1ms
[INFO] GET /src/hooks/use-tts.ts 200 in 0ms
[INFO] GET /src/components/ui/collapsible.tsx 200 in 1ms
[INFO] GET /src/components/ui/alert-dialog.tsx 200 in 1ms
[INFO] GET /src/hooks/use-audio.ts 200 in 1ms
[INFO] GET /src/components/AudioPlayer.tsx 200 in 1ms
[INFO] GET /src/components/ui/dialog.tsx 304 in 1ms
[INFO] GET /src/components/ui/label.tsx 304 in 1ms
[INFO] GET /src/components/ui/progress.tsx 304 in 1ms
[INFO] GET /src/components/ui/slider.tsx 304 in 2ms
[INFO] GET /src/components/ui/popover.tsx 304 in 1ms
[INFO] GET /src/components/ui/select.tsx 304 in 1ms
[INFO] GET /api/user 401 in 7ms
[INFO] GET / 200 in 6ms
[INFO] GET /@vite/client 304 in 1ms
[INFO] GET /src/main.tsx 304 in 1ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 1ms
[INFO] GET /@react-refresh 304 in 1ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 1ms
[INFO] GET /src/index.css 304 in 1ms
[INFO] GET /src/lib/queryClient.ts 304 in 1ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 1ms
[INFO] GET /src/pages/HomePage.tsx 304 in 1ms
[INFO] GET /src/pages/AuthPage.tsx 304 in 1ms
[INFO] GET /src/pages/LibraryPage.tsx 304 in 0ms
[INFO] GET /src/pages/PricingPage.tsx 304 in 0ms
[INFO] GET /src/pages/AdminPage.tsx 304 in 1ms
[INFO] GET /src/pages/ProfilePage.tsx 304 in 0ms
[INFO] GET /src/pages/BillingPage.tsx 304 in 0ms
[INFO] GET /src/hooks/use-user.ts 304 in 1ms
[INFO] GET /src/components/ui/button.tsx 304 in 0ms
[INFO] GET /src/components/Sidebar.tsx 304 in 0ms
[INFO] GET /src/hooks/use-tts.ts 304 in 1ms
[INFO] GET /src/hooks/use-toast.ts 304 in 1ms
[INFO] GET /src/pages/ForgotPasswordPage.tsx 304 in 1ms
[INFO] GET /src/components/Logo.tsx 304 in 1ms
[INFO] GET /src/components/ui/collapsible.tsx 304 in 0ms
[INFO] GET /src/components/UsageProgress.tsx 304 in 0ms
[INFO] GET /@fs/home/runner/PodCasterella/db/schema.ts 304 in 1ms
[INFO] GET /src/components/ui/toast.tsx 304 in 0ms
[INFO] GET /src/components/ui/input.tsx 304 in 0ms
[INFO] GET /src/components/ui/alert-dialog.tsx 304 in 1ms
[INFO] GET /src/components/ui/form.tsx 304 in 1ms
[INFO] GET /src/hooks/use-audio.ts 304 in 0ms
[INFO] GET /src/lib/utils.ts 304 in 1ms
[INFO] GET /src/components/AudioPlayer.tsx 304 in 1ms
[INFO] GET /src/components/ui/card.tsx 304 in 0ms
[INFO] GET /src/components/PaymentModal.tsx 304 in 1ms
[INFO] GET /src/components/ui/tabs.tsx 304 in 0ms
[INFO] GET /src/components/LoadingScreen.tsx 304 in 0ms
[INFO] GET /src/components/ui/separator.tsx 304 in 0ms
[INFO] GET /src/components/ui/scroll-area.tsx 304 in 0ms
[INFO] GET /src/components/ui/avatar.tsx 304 in 0ms
[INFO] GET /src/components/ui/progress.tsx 304 in 1ms
[INFO] GET /src/components/ui/label.tsx 304 in 1ms
[INFO] GET /src/components/ui/slider.tsx 304 in 1ms
[INFO] GET /src/components/ui/popover.tsx 304 in 0ms
[INFO] GET /src/components/ui/dialog.tsx 304 in 1ms
[INFO] GET /src/components/ui/select.tsx 304 in 0ms
[INFO] GET /api/user 401 in 1ms
[INFO] GET / 200 in 4ms
[INFO] Stripe initialized successfully
[INFO] ***Starting server initialization...


[INFO] Registering routes...
[INFO] Setting up Vite for development...
[INFO] Server started successfully on port 4000
[INFO] Webhook endpoint available at: https://PodCasterella.VivekGopal1.repl.co/api/webhooks/stripe
[INFO] GET / 200 in 40ms
[INFO] GET /@vite/client 304 in 20ms
[INFO] GET /src/main.tsx 304 in 85ms
[INFO] GET /@react-refresh 304 in 71ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 1ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 320ms
[INFO] GET /src/pages/LibraryPage.tsx 304 in 0ms
[INFO] GET /src/pages/AuthPage.tsx 304 in 1ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 1ms
[INFO] GET /src/lib/queryClient.ts 304 in 1ms
[INFO] GET /src/pages/ProfilePage.tsx 304 in 2ms
[INFO] GET /src/pages/AdminPage.tsx 304 in 1ms
[INFO] GET /src/pages/HomePage.tsx 304 in 1ms
[INFO] GET /src/pages/BillingPage.tsx 304 in 1ms
[INFO] GET /src/pages/PricingPage.tsx 304 in 1ms
[INFO] GET /src/hooks/use-user.ts 304 in 1ms
[INFO] GET /src/components/ui/button.tsx 304 in 1ms
[INFO] GET /src/index.css 304 in 1668ms
[INFO] GET /src/pages/ForgotPasswordPage.tsx 304 in 0ms
[INFO] GET /src/components/Sidebar.tsx 304 in 0ms
[INFO] GET /src/components/ui/alert-dialog.tsx 304 in 1ms
[INFO] GET /src/hooks/use-audio.ts 304 in 0ms
[INFO] GET /src/components/AudioPlayer.tsx 304 in 0ms
[INFO] GET /src/hooks/use-toast.ts 304 in 0ms
[INFO] GET /src/lib/utils.ts 304 in 0ms
[INFO] GET /src/components/ui/form.tsx 304 in 1ms
[INFO] GET /src/components/ui/toast.tsx 304 in 1ms
[INFO] GET /src/components/ui/input.tsx 304 in 1ms
[INFO] GET /@fs/home/runner/PodCasterella/db/schema.ts 304 in 1ms
[INFO] GET /src/components/ui/tabs.tsx 304 in 1ms
[INFO] GET /src/hooks/use-tts.ts 304 in 0ms
[INFO] GET /src/components/Logo.tsx 304 in 1ms
[INFO] GET /src/components/ui/avatar.tsx 304 in 0ms
[INFO] GET /src/components/ui/card.tsx 304 in 0ms
[INFO] GET /src/components/UsageProgress.tsx 304 in 0ms
[INFO] GET /src/components/ui/collapsible.tsx 304 in 1ms
[INFO] GET /src/components/PaymentModal.tsx 304 in 0ms
[INFO] GET /src/components/ui/scroll-area.tsx 304 in 0ms
[INFO] GET /src/components/ui/separator.tsx 304 in 0ms
[INFO] GET /src/components/LoadingScreen.tsx 304 in 1ms
[INFO] GET /src/components/ui/slider.tsx 304 in 1ms
[INFO] GET /src/components/ui/popover.tsx 304 in 0ms
[INFO] GET /src/components/ui/select.tsx 304 in 0ms
[INFO] GET /src/components/ui/dialog.tsx 304 in 0ms
[INFO] GET /src/components/ui/progress.tsx 304 in 1ms
[INFO] GET /src/components/ui/label.tsx 304 in 1ms
[INFO] GET /api/user 401 in 3ms
[INFO] GET / 200 in 5ms
[INFO] GET /@vite/client 304 in 1ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 1ms
[INFO] GET /src/main.tsx 304 in 0ms
[INFO] GET /@react-refresh 304 in 0ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 1ms
[INFO] GET /src/index.css 304 in 0ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 0ms
[INFO] GET /src/lib/queryClient.ts 304 in 0ms
[INFO] GET /src/pages/AuthPage.tsx 304 in 1ms
[INFO] GET /src/pages/HomePage.tsx 304 in 0ms
[INFO] GET /src/pages/LibraryPage.tsx 304 in 1ms
[INFO] GET /src/pages/AdminPage.tsx 304 in 0ms
[INFO] GET /src/pages/PricingPage.tsx 304 in 0ms
[INFO] GET /src/pages/ProfilePage.tsx 304 in 1ms
[INFO] GET /src/pages/BillingPage.tsx 304 in 0ms
[INFO] GET /src/hooks/use-user.ts 304 in 0ms
[INFO] GET /src/components/Sidebar.tsx 304 in 1ms
[INFO] GET /src/pages/ForgotPasswordPage.tsx 304 in 0ms
[INFO] GET /src/components/ui/button.tsx 304 in 0ms
[INFO] GET /src/components/ui/toast.tsx 304 in 0ms
[INFO] GET /src/hooks/use-toast.ts 304 in 1ms
[INFO] GET /@fs/home/runner/PodCasterella/db/schema.ts 304 in 0ms
[INFO] GET /src/components/ui/input.tsx 304 in 1ms
[INFO] GET /src/components/ui/form.tsx 304 in 0ms
[INFO] GET /src/components/Logo.tsx 304 in 0ms
[INFO] GET /src/hooks/use-tts.ts 304 in 0ms
[INFO] GET /src/components/UsageProgress.tsx 304 in 1ms
[INFO] GET /src/components/ui/collapsible.tsx 304 in 0ms
[INFO] GET /src/components/ui/alert-dialog.tsx 304 in 1ms
[INFO] GET /src/components/AudioPlayer.tsx 304 in 1ms
[INFO] GET /src/lib/utils.ts 304 in 1ms
[INFO] GET /src/hooks/use-audio.ts 304 in 0ms
[INFO] GET /src/components/ui/card.tsx 304 in 1ms
[INFO] GET /src/components/ui/tabs.tsx 304 in 1ms
[INFO] GET /src/components/ui/avatar.tsx 304 in 0ms
[INFO] GET /src/components/PaymentModal.tsx 304 in 0ms
[INFO] GET /src/components/ui/separator.tsx 304 in 0ms
[INFO] GET /src/components/LoadingScreen.tsx 304 in 0ms
[INFO] GET /src/components/ui/scroll-area.tsx 304 in 1ms
[INFO] GET /src/components/ui/label.tsx 304 in 0ms
[INFO] GET /src/components/ui/progress.tsx 304 in 1ms
[INFO] GET /src/components/ui/slider.tsx 304 in 0ms
[INFO] GET /src/components/ui/popover.tsx 304 in 0ms
[INFO] GET /src/components/ui/select.tsx 304 in 0ms
[INFO] GET /src/components/ui/dialog.tsx 304 in 1ms
[INFO] GET /api/user 401 in 1ms
[INFO] GET / 200 in 2ms
[INFO] POST /api/login 200 in 377ms
[INFO] GET /api/user 304 in 63ms
[INFO] GET / 200 in 65ms
[INFO] GET / 200 in 97ms
[INFO] GET /api/playlists 304 in 264ms
[INFO] GET /api/podcasts 304 in 311ms
[INFO] GET / 200 in 64ms
[INFO] 
========Streaming audio file: 1735651217703-article.mp3
[INFO] ========Range undefined
[INFO] HEAD /api/audio/stream/1735651217703-article.mp3 200 in 944ms
[INFO] 
========Streaming audio file: 1735651217703-article.mp3
[INFO] ========Range bytes=0-
[INFO] HEAD / 200 in 62ms
[INFO] GET / 200 in 61ms
[INFO] HEAD / 200 in 61ms
[INFO] GET / 200 in 70ms
[INFO] HEAD / 200 in 61ms
[INFO] GET / 200 in 60ms
[INFO] Stripe initialized successfully
[INFO] ***Starting server initialization...


[INFO] Registering routes...
[INFO] Setting up Vite for development...
[INFO] Server started successfully on port 4000
[INFO] Webhook endpoint available at: https://PodCasterella.VivekGopal1.repl.co/api/webhooks/stripe
[INFO] GET / 200 in 43ms
[INFO] GET /@vite/client 304 in 37ms
[INFO] GET /src/main.tsx 304 in 76ms
[INFO] GET /@react-refresh 304 in 6ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 2ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 1148ms
[INFO] GET /src/pages/AuthPage.tsx 304 in 1ms
[INFO] GET /src/pages/LibraryPage.tsx 304 in 2ms
[INFO] GET /src/lib/queryClient.ts 304 in 2ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 1ms
[INFO] GET /src/pages/HomePage.tsx 304 in 2ms
[INFO] GET /src/index.css 304 in 715ms
[INFO] GET /src/pages/ProfilePage.tsx 304 in 1ms
[INFO] GET /src/pages/PricingPage.tsx 304 in 1ms
[INFO] GET /src/components/Sidebar.tsx 304 in 1ms
[INFO] GET /src/pages/ForgotPasswordPage.tsx 304 in 1ms
[INFO] GET /src/components/ui/button.tsx 304 in 1ms
[INFO] GET /src/pages/AdminPage.tsx 304 in 0ms
[INFO] GET /src/hooks/use-user.ts 304 in 1ms
[INFO] GET /src/pages/BillingPage.tsx 304 in 1ms
[INFO] GET /src/hooks/use-toast.ts 304 in 1ms
[INFO] GET /src/hooks/use-audio.ts 304 in 1ms
[INFO] GET /src/components/ui/input.tsx 304 in 1ms
[INFO] GET /src/components/ui/toast.tsx 304 in 2ms
[INFO] GET /src/components/ui/form.tsx 304 in 1ms
[INFO] GET /src/lib/utils.ts 304 in 1ms
[INFO] GET /src/components/AudioPlayer.tsx 304 in 1ms
[INFO] GET /src/components/ui/collapsible.tsx 304 in 1ms
[INFO] GET /src/components/UsageProgress.tsx 304 in 0ms
[INFO] GET /@fs/home/runner/PodCasterella/db/schema.ts 304 in 0ms
[INFO] GET /src/hooks/use-tts.ts 304 in 0ms
[INFO] GET /src/components/Logo.tsx 304 in 0ms
[INFO] GET /src/components/ui/alert-dialog.tsx 304 in 8ms
[INFO] GET /src/components/ui/avatar.tsx 304 in 7ms
[INFO] GET /src/components/ui/card.tsx 304 in 0ms
[INFO] GET /src/components/ui/scroll-area.tsx 304 in 1ms
[INFO] GET /src/components/ui/tabs.tsx 304 in 1ms
[INFO] GET /src/components/LoadingScreen.tsx 304 in 0ms
[INFO] GET /src/components/ui/separator.tsx 304 in 1ms
[INFO] GET /src/components/ui/label.tsx 304 in 1ms
[INFO] GET /src/components/PaymentModal.tsx 304 in 1ms
[INFO] GET /src/components/ui/slider.tsx 304 in 0ms
[INFO] GET /src/components/ui/popover.tsx 304 in 0ms
[INFO] GET /src/components/ui/select.tsx 304 in 1ms
[INFO] GET /src/components/ui/dialog.tsx 304 in 1ms
[INFO] GET /src/components/ui/progress.tsx 304 in 1ms
[INFO] GET /api/user 401 in 2ms
[INFO] GET / 200 in 10ms
[INFO] GET /src/main.tsx 304 in 1ms
[INFO] GET /@vite/client 304 in 1ms
[INFO] GET /@vite-plugin-checker-runtime 304 in 1ms
[INFO] GET /@react-refresh 304 in 1ms
[INFO] GET /src/index.css 304 in 0ms
[INFO] GET /src/lib/queryClient.ts 304 in 0ms
[INFO] GET /src/components/ui/toaster.tsx 304 in 1ms
[INFO] GET /src/pages/HomePage.tsx 304 in 1ms
[INFO] GET /src/pages/AuthPage.tsx 304 in 0ms
[INFO] GET /src/pages/LibraryPage.tsx 304 in 1ms
[INFO] GET /src/pages/PricingPage.tsx 304 in 1ms
[INFO] GET /src/pages/AdminPage.tsx 304 in 1ms
[INFO] GET /src/pages/ProfilePage.tsx 304 in 1ms
[INFO] GET /src/pages/BillingPage.tsx 304 in 1ms
[INFO] GET /src/hooks/use-user.ts 304 in 0ms
[INFO] GET /src/components/Sidebar.tsx 304 in 1ms
[INFO] GET /src/pages/ForgotPasswordPage.tsx 304 in 0ms
[INFO] GET /src/components/ui/button.tsx 304 in 0ms
[INFO] GET /@fs/home/runner/PodCasterella/node_modules/vite/dist/client/env.mjs 304 in 1ms
[INFO] GET /src/hooks/use-toast.ts 304 in 1ms
[INFO] GET /src/components/ui/toast.tsx 304 in 0ms
[INFO] GET /src/hooks/use-tts.ts 304 in 1ms
[INFO] GET /src/components/Logo.tsx 304 in 0ms
[INFO] GET /src/components/UsageProgress.tsx 304 in 0ms
[INFO] GET /src/components/ui/collapsible.tsx 304 in 1ms
[INFO] GET /@fs/home/runner/PodCasterella/db/schema.ts 304 in 1ms
[INFO] GET /src/components/ui/input.tsx 304 in 0ms
[INFO] GET /src/components/ui/form.tsx 304 in 0ms
[INFO] GET /src/components/ui/alert-dialog.tsx 304 in 2ms
[INFO] GET /src/hooks/use-audio.ts 304 in 0ms
[INFO] GET /src/components/AudioPlayer.tsx 304 in 1ms
[INFO] GET /src/lib/utils.ts 304 in 1ms
[INFO] GET /src/components/ui/card.tsx 304 in 0ms
[INFO] GET /src/components/ui/avatar.tsx 304 in 1ms
[INFO] GET /src/components/ui/tabs.tsx 304 in 1ms
[INFO] GET /src/components/PaymentModal.tsx 304 in 0ms
[INFO] GET /src/components/LoadingScreen.tsx 304 in 0ms
[INFO] GET /src/components/ui/separator.tsx 304 in 0ms
[INFO] GET /src/components/ui/scroll-area.tsx 304 in 0ms
[INFO] GET /src/components/ui/progress.tsx 304 in 0ms
[INFO] GET /src/components/ui/label.tsx 304 in 1ms
[INFO] GET /src/components/ui/slider.tsx 304 in 1ms
[INFO] GET /src/components/ui/popover.tsx 304 in 1ms
[INFO] GET /src/components/ui/select.tsx 304 in 1ms
[INFO] GET /src/components/ui/dialog.tsx 304 in 0ms
[INFO] GET /api/user 401 in 1ms
[INFO] GET / 200 in 4ms
[INFO] POST /api/login 200 in 369ms
[INFO] GET /api/user 304 in 60ms
[INFO] GET / 200 in 61ms
[INFO] GET / 200 in 85ms
[INFO] GET /api/podcasts 200 in 245ms
[INFO] GET /api/playlists 304 in 246ms
[INFO] GET / 200 in 63ms
[INFO] GET / 200 in 113ms
[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 200 in 240ms
[INFO] Calculating estimated pricing and checking usage limits
[INFO] 
======= Starting Pricing Calculation ======
 -Input text length: 16704
 -Number of Vertex AI responses: 0

[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 119ms
[INFO] 
        Input text length: 16704
        Input token count: 3419
        System prompt length: 2718
        System token count: 525
        Total input tokens: 3944
      
[INFO] 
---***** Estimated Calculation Summary **** ---
Total Input Tokens: 3944
Total Output Tokens: 5916
Total Tokens: 9860
Total TTS Characters: 23664
Vertex AI Input Cost: $0.000002
Vertex AI Output Cost: $0.000003
TTS Cost: $0.378624
Total Cost: $0.378629
[INFO] Estimated Podify Tokens: 190 

Usage limits check for user 24:
 Current articles: 0/3
 Current Podify tokens: 0/10000
 Would exceed article limit: false
 Would exceed token limit: false
[INFO] Starting audio generation process
[INFO] 
--- Starting Conversation Generation ---

[INFO] 

 ------------PROMPT to VERTEX AI-----------------
 Speaker Joe should Start the podcast by saying this: Welcome to Science Odyssey, the podcast where we journey through groundbreaking scientific studies,
unraveling the mysteries behind the research that shapes our world. Thanks for tuning in!

**Guidelines**:
1. Joe provides detailed technical insights but avoids overusing analogies. Instead, focus on straightforward, clear explanations.
2. Sarah asks probing, thoughtful questions, occasionally offers her own insights, and challenges Joe to explain concepts simply and conversationally.
3. Both speakers use natural human speech patterns, including filler words like "um," "ah," "you know," and short pauses.

**Focus**:
- Avoid excessive use of analogies. Use one or two if necessary for clarity but prioritize clear, direct explanations.
- Include natural conversational flow with interruptions, backtracking, and filler words to make the dialogue feel authentic.
- Encourage a natural dialogue with varied contributions from both speakers.

**Tone**:
- Engaging, relatable, and spontaneous.
- Emphasize human-like emotions, with occasional humor or lighthearted moments.
- Balance technical depth with conversational relatability, avoiding overly formal language.

You are generating a podcast conversation between Joe and Sarah.

**Guidelines**:
1. Joe provides detailed technical insights but avoids overusing analogies. Instead, focus on straightforward, clear explanations.
2. Sarah asks probing, thoughtful questions, occasionally offers her own insights, and challenges Joe to explain concepts simply and conversationally.
3. Both speakers use natural human speech patterns, including filler words like "you know," and short pauses.
4. Don't include any sound effects or background music.

**Focus**:
- Avoid excessive use of analogies. Use one or two if necessary for clarity but prioritize clear, direct explanations.
- Include natural conversational flow with interruptions, backtracking, and filler words to make the dialogue feel authentic.
- Encourage a natural dialogue with varied contributions from both speakers.

**Tone**:
- Engaging, relatable, and spontaneous.
- Emphasize human-like emotions, with occasional humor or lighthearted moments.
- Balance technical depth with conversational relatability, avoiding overly formal language.

Joe: C arl Laflamme knew what protein he wanted to study, but not where to find it. It is encoded by a gene called C9ORF72, which is mutated in some people with the devastating neuro- logical condition motor neuron disease, also known as amyotrophic lateral sclerosis. And Laflamme wanted to understand its role in the disease. When he started his postdoctoral fellowship at the Montreal Neurological Institute-Hospital in Canada, Laflamme scoured the literature, searching for information on the protein. The problem was that none of the papers seemed to agree where in the cell this mysterious mol- ecule operates. There was so much confusion in the field, Laflamme says. He wondered whether a reagent was to blame, in particular the antibodies that scientists used to measure the amount of the protein and track its position in the cell. So, he and his colleagues decided to test the antibodies that were available. They identified 16 commercial antibodies that were adver- tised as able to bind to the protein encoded by C9ORF72. When the researchers put them THE QUEST TO RID LABS OF THE REAGENTS THAT RUIN EXPERIMENTS Poorly performing antibodies have plagued biomedicalsciences for decades. Several fresh initiativeshope to change this. By Diana Kwon ILLUSTRATION BY FABIO BUONOCORE 26 | Nature | Vol 635 | 7 November 2024 Feature through their paces, only three performed wellmeaning that the antibodies bound to the protein of interest without binding to other molecules. But not one published study had used these antibodies. About 15 papers described experiments using an antibody that didnt even bind the key protein in Laflammes testing. And those papers had been collec- tively cited more than 3,000 times 1 . Laflammes experience isnt unusual. Scien- tists have long known that many commercial antibodies dont work as they should they often fail to recognize a specific protein or non-selectively bind to several other targets. The result is a waste of time and resources that some say has contributed to a repro - ducibility crisis in the biological sciences, potentially slowing the pace of discovery and drug development. Laflamme is part of a growing community that wants to solve the problem of unreliable antibodies in research. He teamed up with molecular geneticist Aled Edwards at the University of Toronto, Canada, to set up Antibody Characterization through Open Science (YCharOS, pronounced Icarus), an initiative that aims to characterize commer- cially available research antibodies for every human protein. There are also efforts under way to produce better-performing antibodies, to make it easier for researchers to find them and to encourage the research community to adopt best prac- tices when it comes to choosing and working with these molecules. Antibody vendors, funding agencies and scientific publishers are all getting in on the action, says Harvinder Virk, a physicianscientist at the University of Leicester, UK. Its hard to imagine that a problem that has been going on so long will suddenly change but Im hopeful. Putting antibodies to the test The immune system produces antibodies in response to foreign substances, such as viruses and bacteria, flagging them for destruction. This makes antibodies useful in laboratory experiments. Scientists co-opt this ability by using them to mark or quantify spe- cific biological molecules, such as a segment of a protein. To be effective, these molecular tags need to have both specificity a strong affinity for the target and selectivity the ability to leave other proteins unmarked. For decades, scientists created these anti- bodies themselves. They injected proteins into animals, such as rabbits, whose immune systems would generate antibodies against the foreign molecules. To create a longer- term, more consistent supply of antibodies, researchers extracted immune cells from ani- mals and combined them with immortalized cancer cells.

Sarah: 

 ------------END-----------------

[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 114ms
[INFO] 

 -------RESPONSE FROM VERTEX AI---------
 Joe: Welcome to Science Odyssey, the podcast where we journey through groundbreaking scientific studies, unraveling the mysteries behind the research that shapes our world. Thanks for tuning in!  Today, we're diving into a fascinating, and frankly, slightly frustrating, area of scientific research: antibodies.  Specifically, the problem of unreliable antibodies in biomedical research.

Sarah:  Oh, this sounds… interesting.  I mean, I've heard whispers about reproducibility issues in science, but I haven't really understood the specifics.  Antibodies…aren't those, like, the things your body uses to fight off infections?

Joe: Exactly!  That's the basic principle.  Our immune systems produce antibodies to target specific invaders, like viruses or bacteria.  Scientists have cleverly harnessed this process to, um,  study proteins and other molecules in the lab. We use antibodies to, you know, identify and quantify specific proteins within a cell,  to essentially label them and see where they are and how much is there.

Sarah: Okay, I'm following so far.  But what's the problem?  Why are unreliable antibodies such a big deal?

Joe:  Well, the problem is that, for years, many commercially available antibodies haven't actually worked as advertised.  A lot of them either don't bind to the intended protein at all, or they bind to other things too, giving you false positive results.  Think of it like... um... trying to find a specific, rare coin in a pile of coins.  If your tool, the antibody, is faulty and grabs other coins as well,  you're never going to find the right one.  You'll get a lot of false results.

Sarah: So, you're saying researchers are essentially wasting time and resources on experiments that might be based on flawed data?

Joe:  Precisely.  Carl Laflamme, a researcher we're discussing today,  found this out firsthand.  He was studying a protein linked to a neurodegenerative disease, and he spent a lot of time trying to figure out where this protein was located within the cell.  He looked through tons of research papers, only to discover that many of them had used antibodies that simply didn't work properly.  He tested sixteen commercially available antibodies that *claimed* to bind to this specific protein and only three actually did.  And those three weren't used in any of the previously published papers!

Sarah:  Wow. So,  hundreds, thousands of research papers might be based on unreliable data because of these faulty antibodies?  That’s a huge problem.

Joe:  Exactly. It's contributed to what some call a "reproducibility crisis" in biology.  It means that a lot of research findings are hard, or even impossible, to replicate.  It slows down scientific progress, and it's a massive waste of time and money.  That's why initiatives like  Antibody Characterization through Open Science, or iCharOS, are so crucial. They aim to rigorously test and characterize commercially available antibodies to ensure their reliability.

Sarah:  That sounds like a monumental task.  How many antibodies are we talking about?

Joe:  Oh, it's huge. They're aiming to characterize antibodies for every single human protein.  It's a massive undertaking, but hopefully, it will create a much more reliable foundation for future research.  It's a clear example of how even seemingly small, technical issues can have massive consequences for the entire scientific field.

Sarah:  Definitely.  This highlights the importance of transparency and rigorous quality control in scientific research.  Thanks for explaining this, Joe. It's a lot more complicated than I initially thought.

Joe: My pleasure, Sarah.  It's a complex issue, but hopefully, we've shed some light on it.  And that's all the time we have for today's episode of Science Odyssey.  Join us next time for more fascinating journeys into the world of science.
 

 ------------END-----------------

[INFO] Processing 13 lines of text
[INFO] Added conversation part: Joe with Welcome to Science Odyssey, the podcast where we j...
[INFO] Added conversation part: Sarah with Oh, this sounds… interesting.  I mean, I've heard ...
[INFO] Added conversation part: Joe with Exactly!  That's the basic principle.  Our immune ...
[INFO] Added conversation part: Sarah with Okay, I'm following so far.  But what's the proble...
[INFO] Added conversation part: Joe with Well, the problem is that, for years, many commerc...
[INFO] Added conversation part: Sarah with So, you're saying researchers are essentially wast...
[INFO] Added conversation part: Joe with Precisely.  Carl Laflamme, a researcher we're disc...
[INFO] Added conversation part: Sarah with Wow. So,  hundreds, thousands of research papers m...
[INFO] Added conversation part: Joe with Exactly. It's contributed to what some call a "rep...
[INFO] Added conversation part: Sarah with That sounds like a monumental task.  How many anti...
[INFO] Added conversation part: Joe with Oh, it's huge. They're aiming to characterize anti...
[INFO] Added conversation part: Sarah with Definitely.  This highlights the importance of tra...
[INFO] Added conversation part: Joe with My pleasure, Sarah.  It's a complex issue, but hop...
[INFO] Successfully extracted 13 conversation parts
[INFO] Cleaned Text (Chunk 1): [
  {
    "speaker": "Joe",
    "text": "Welcome to Science Odyssey, the podcast where we journey through groundbreaking scientific studies, unraveling the mysteries behind the research that shapes our world. Thanks for tuning in!  Today, we're diving into a fascinating, and frankly, slightly frustrating, area of scientific research: antibodies.  Specifically, the problem of unreliable antibodies in biomedical research."
  },
  {
    "speaker": "Sarah",
    "text": "Oh, this sounds… interesting.  I mean, I've heard whispers about reproducibility issues in science, but I haven't really understood the specifics.  Antibodies…aren't those, like, the things your body uses to fight off infections?"
  },
  {
    "speaker": "Joe",
    "text": "Exactly!  That's the basic principle.  Our immune systems produce antibodies to target specific invaders, like viruses or bacteria.  Scientists have cleverly harnessed this process to, um,  study proteins and other molecules in the lab. We use antibodies to, you know, identify and quantify specific proteins within a cell,  to essentially label them and see where they are and how much is there."
  },
  {
    "speaker": "Sarah",
    "text": "Okay, I'm following so far.  But what's the problem?  Why are unreliable antibodies such a big deal?"
  },
  {
    "speaker": "Joe",
    "text": "Well, the problem is that, for years, many commercially available antibodies haven't actually worked as advertised.  A lot of them either don't bind to the intended protein at all, or they bind to other things too, giving you false positive results.  Think of it like... um... trying to find a specific, rare coin in a pile of coins.  If your tool, the antibody, is faulty and grabs other coins as well,  you're never going to find the right one.  You'll get a lot of false results."
  },
  {
    "speaker": "Sarah",
    "text": "So, you're saying researchers are essentially wasting time and resources on experiments that might be based on flawed data?"
  },
  {
    "speaker": "Joe",
    "text": "Precisely.  Carl Laflamme, a researcher we're discussing today,  found this out firsthand.  He was studying a protein linked to a neurodegenerative disease, and he spent a lot of time trying to figure out where this protein was located within the cell.  He looked through tons of research papers, only to discover that many of them had used antibodies that simply didn't work properly.  He tested sixteen commercially available antibodies that *claimed* to bind to this specific protein and only three actually did.  And those three weren't used in any of the previously published papers!"
  },
  {
    "speaker": "Sarah",
    "text": "Wow. So,  hundreds, thousands of research papers might be based on unreliable data because of these faulty antibodies?  That’s a huge problem."
  },
  {
    "speaker": "Joe",
    "text": "Exactly. It's contributed to what some call a \"reproducibility crisis\" in biology.  It means that a lot of research findings are hard, or even impossible, to replicate.  It slows down scientific progress, and it's a massive waste of time and money.  That's why initiatives like  Antibody Characterization through Open Science, or iCharOS, are so crucial. They aim to rigorously test and characterize commercially available antibodies to ensure their reliability."
  },
  {
    "speaker": "Sarah",
    "text": "That sounds like a monumental task.  How many antibodies are we talking about?"
  },
  {
    "speaker": "Joe",
    "text": "Oh, it's huge. They're aiming to characterize antibodies for every single human protein.  It's a massive undertaking, but hopefully, it will create a much more reliable foundation for future research.  It's a clear example of how even seemingly small, technical issues can have massive consequences for the entire scientific field."
  },
  {
    "speaker": "Sarah",
    "text": "Definitely.  This highlights the importance of transparency and rigorous quality control in scientific research.  Thanks for explaining this, Joe. It's a lot more complicated than I initially thought."
  },
  {
    "speaker": "Joe",
    "text": "My pleasure, Sarah.  It's a complex issue, but hopefully, we've shed some light on it.  And that's all the time we have for today's episode of Science Odyssey.  Join us next time for more fascinating journeys into the world of science."
  }
]
[INFO] 

 ------------PROMPT to VERTEX AI-----------------
 You are generating a podcast conversation between Joe and Sarah.

**Guidelines**:
1. Joe provides detailed technical insights but avoids overusing analogies. Instead, focus on straightforward, clear explanations.
2. Sarah asks probing, thoughtful questions, occasionally offers her own insights, and challenges Joe to explain concepts simply and conversationally.
3. Both speakers use natural human speech patterns, including filler words like "you know," and short pauses.
4. Don't include any sound effects or background music.

**Focus**:
- Avoid excessive use of analogies. Use one or two if necessary for clarity but prioritize clear, direct explanations.
- Include natural conversational flow with interruptions, backtracking, and filler words to make the dialogue feel authentic.
- Encourage a natural dialogue with varied contributions from both speakers.

**Tone**:
- Engaging, relatable, and spontaneous.
- Emphasize human-like emotions, with occasional humor or lighthearted moments.
- Balance technical depth with conversational relatability, avoiding overly formal language.

**Previous Context**:
My pleasure, Sarah.  It's a complex issue, but hopefully, we've shed some light on it.  And that's all the time we have for today's episode of Science Odyssey.  Join us next time for more fascinating journeys into the world of science.

Sarah: When reagent companies began the mass production of antibodies in the 1990s, most researchers shifted to purchasing antibodies from a catalogue. Today, there are around 7.7 million research antibody products on the market, sold by almost 350antibody suppliers around the world. In the late 2000s, scientists began reporting problems with both the specificity and selectivity of many commercially available antibodies, leading researchers to call for an independent body to certify that the molecules work as advertised. Over the years, a handful of groups have launched efforts to evaluate antibodies. What sets YCharOS apart is the level of cooperation that it has obtained from com- panies that sell antibodies. When Laflamme and Edwards set out to start YCharOS, they called every single vendor they could find; more than a dozen were interested in collab- orating. YCharOSs industry partners provide the antibodies for testing, free of charge. The partners, along with the funders of the initia- tive (which include various non-profit organ- izations and funding agencies), are given the chance to review characterization reports and provide feedback before they are published. YCharOS tests antibodies by comparing their specificity in a cell line that expresses the target protein at normal biological levels against their performance in whats called a knock-out cell line that lacks the protein (see Ways to validate). In an analysis published in eLife last year, the YCharOS team used this method to assess 614commercial antibodies, targeting a total of 65neuroscience-related proteins 2 . Two- thirds of them did not work as recommended by manufacturers. It never fails to amaze me how much of a hit or miss antibodies are, says Riham Ayoubi, director of operations at YCharOS. It shows you how important it is to include that nega- tive control in the work. Antibody manufacturers reassessed more than half of the underperforming antibodies that YCharOS flagged in 2023. They issued updated recommendations for 153 of them and removed 73 from the market. The YCharOS team has now tested more than 1,000 anti- bodies that are meant to bind to more than 100human proteins. Theres still a lot of work ahead, Laflamme says. He estimates that, of the 1.6 million commercially available antibodies to human proteins, roughly 200,000 are unique (many suppliers sell the same antibodies under different names). I think the YCharOS initiative can really make a difference, says Cecilia Williams, a cancer researcher at the KTH Royal Institute of Technology in Stockholm. But its not everything, because researchers will use these antibodies in other protocols, and in other tissues and cells that may express the protein differently, she says. The context in which anti- bodies are used can change how they perform. Other characterization efforts are trying to tackle this challenge. Andrea Radtke and her collaborators were part of a cell-mapping con- sortium called the Human BioMolecular Atlas Program when they set up the Organ Mapping Antibody Panels (OMAPs). OMAPs are col- lections of community-validated antibodies used in multiplex imaging a technique that involves visualizing several proteins in a single specimen. Unlike YCharOS, which focuses on conducting rigorous characterizations of antibodies for various applications in one specific context, OMAPs is looking at a single application for the antibodies, but in several contexts, such as in different human tissues and imaging methods. To do so, OMAPs recruits scientists from both academia and industry to conduct validations in their own labs. Vendors cannot test all possible applica- tions of their antibodies, but as a community we can say lets try this, says Radtke, who now works as a principal scientist at the instru- mentation company Leica Microsystems in Bethesda, Maryland. People are testing things that you would never think you could test. 

 ------------END-----------------

[INFO] 

 -------RESPONSE FROM VERTEX AI---------
 **(Sound of a gentle transition, then silence)**

**Joe:** So, Sarah, we’ve talked about the antibody crisis, the sheer volume of commercially available antibodies, and the resulting problems with reliability.  But YCharOS, as you highlighted, is attempting to address this head-on, right?

**Sarah:** Right. It’s fascinating.  The scale of the problem – millions of antibodies, many not working as advertised – is just staggering.  But what really impressed me about YCharOS is their collaborative approach.  They're not just testing, they're working *with* the manufacturers.  That's a huge difference, isn't it? I mean, it's not just about pointing fingers, it's about fixing the problem.

**Joe:** Exactly.  Their method focuses on comparing antibody specificity in cell lines that express the target protein at normal levels versus those lacking the protein – a knockout cell line, as you mentioned.  This direct comparison allows for a very clear assessment of whether the antibody binds specifically to the intended target. No fancy analogies needed, just straightforward comparison.  It’s a powerful, relatively simple approach.

**Sarah:**  So, it’s a sort of…  a control group, but at a cellular level?  It's not just about, say, comparing results against a blank sample, but a sample specifically designed to *lack* the target protein?

**Joe:** Precisely.  It's a negative control, crucial for determining true specificity.  If the antibody binds significantly in the knockout cell line, that indicates non-specific binding, which is a major problem.  YCharOS's results, showing that two-thirds of the antibodies tested didn't perform as claimed, highlight the scale of the issue.  It's not just a little bit off; it's a significant failure rate.

**Sarah:**  Yeah, that two-thirds figure… it's shocking, honestly.  But what about other initiatives, like OMAPs?  How does their approach differ?

**Joe:** OMAPs takes a different tack.  Instead of focusing on comprehensive characterization of antibodies across various applications, they concentrate on validating antibodies for a *specific* application – multiplex imaging – but across various contexts, like different tissues and imaging methods.  So it's a trade-off; broader contextual validation, but for a narrower application.

**Sarah:** So YCharOS is about comprehensive testing in one context, while OMAPs is about targeted testing across multiple contexts.  That makes sense.  It sounds like both approaches are valuable, offering complementary perspectives on antibody validation.  Um… it's almost like… you know, one's looking at the forest, the other at the trees.  But maybe that's a bad analogy, given our agreement to avoid them!

**Joe:**  (chuckles)  Yes, let's stick to the direct comparisons.  Both approaches are valuable precisely because they address different facets of the same problem.  The need for rigorous validation is undeniable, and these initiatives represent important steps towards improving the reliability of scientific research.  

**Sarah:** Absolutely.  It’s reassuring to see such proactive efforts to address this critical issue.  It seems like collaboration is key here, both between researchers and between researchers and the manufacturers themselves.

**Joe:**  Indeed.  And that’s a really important takeaway.

**(Sound of a gentle transition, then silence)**
 

 ------------END-----------------

[INFO] Processing 13 lines of text
[INFO] No speaker pattern match found at line 1: "**(Sound of a gentle transition, then silence)**..."
[INFO] Added conversation part: Joe with ** So, Sarah, we’ve talked about the antibody cris...
[INFO] Added conversation part: Sarah with ** Right. It’s fascinating.  The scale of the prob...
[INFO] Added conversation part: Joe with ** Exactly.  Their method focuses on comparing ant...
[INFO] Added conversation part: Sarah with **  So, it’s a sort of…  a control group, but at a...
[INFO] Added conversation part: Joe with ** Precisely.  It's a negative control, crucial fo...
[INFO] Added conversation part: Sarah with **  Yeah, that two-thirds figure… it's shocking, h...
[INFO] Added conversation part: Joe with ** OMAPs takes a different tack.  Instead of focus...
[INFO] Added conversation part: Sarah with ** So YCharOS is about comprehensive testing in on...
[INFO] Added conversation part: Joe with **  (chuckles)  Yes, let's stick to the direct com...
[INFO] Added conversation part: Sarah with ** Absolutely.  It’s reassuring to see such proact...
[INFO] Added conversation part: Joe with **  Indeed.  And that’s a really important takeawa...
[INFO] No speaker pattern match found at line 13: "**(Sound of a gentle transition, then silence)**..."
[INFO] Successfully extracted 11 conversation parts
[INFO] Cleaned Text (Chunk 2): [
  {
    "speaker": "Joe",
    "text": "** So, Sarah, we’ve talked about the antibody crisis, the sheer volume of commercially available antibodies, and the resulting problems with reliability.  But YCharOS, as you highlighted, is attempting to address this head-on, right?"
  },
  {
    "speaker": "Sarah",
    "text": "** Right. It’s fascinating.  The scale of the problem – millions of antibodies, many not working as advertised – is just staggering.  But what really impressed me about YCharOS is their collaborative approach.  They're not just testing, they're working *with* the manufacturers.  That's a huge difference, isn't it? I mean, it's not just about pointing fingers, it's about fixing the problem."
  },
  {
    "speaker": "Joe",
    "text": "** Exactly.  Their method focuses on comparing antibody specificity in cell lines that express the target protein at normal levels versus those lacking the protein – a knockout cell line, as you mentioned.  This direct comparison allows for a very clear assessment of whether the antibody binds specifically to the intended target. No fancy analogies needed, just straightforward comparison.  It’s a powerful, relatively simple approach."
  },
  {
    "speaker": "Sarah",
    "text": "**  So, it’s a sort of…  a control group, but at a cellular level?  It's not just about, say, comparing results against a blank sample, but a sample specifically designed to *lack* the target protein?"
  },
  {
    "speaker": "Joe",
    "text": "** Precisely.  It's a negative control, crucial for determining true specificity.  If the antibody binds significantly in the knockout cell line, that indicates non-specific binding, which is a major problem.  YCharOS's results, showing that two-thirds of the antibodies tested didn't perform as claimed, highlight the scale of the issue.  It's not just a little bit off; it's a significant failure rate."
  },
  {
    "speaker": "Sarah",
    "text": "**  Yeah, that two-thirds figure… it's shocking, honestly.  But what about other initiatives, like OMAPs?  How does their approach differ?"
  },
  {
    "speaker": "Joe",
    "text": "** OMAPs takes a different tack.  Instead of focusing on comprehensive characterization of antibodies across various applications, they concentrate on validating antibodies for a *specific* application – multiplex imaging – but across various contexts, like different tissues and imaging methods.  So it's a trade-off; broader contextual validation, but for a narrower application."
  },
  {
    "speaker": "Sarah",
    "text": "** So YCharOS is about comprehensive testing in one context, while OMAPs is about targeted testing across multiple contexts.  That makes sense.  It sounds like both approaches are valuable, offering complementary perspectives on antibody validation.  Um… it's almost like… you know, one's looking at the forest, the other at the trees.  But maybe that's a bad analogy, given our agreement to avoid them!"
  },
  {
    "speaker": "Joe",
    "text": "**  (chuckles)  Yes, let's stick to the direct comparisons.  Both approaches are valuable precisely because they address different facets of the same problem.  The need for rigorous validation is undeniable, and these initiatives represent important steps towards improving the reliability of scientific research."
  },
  {
    "speaker": "Sarah",
    "text": "** Absolutely.  It’s reassuring to see such proactive efforts to address this critical issue.  It seems like collaboration is key here, both between researchers and between researchers and the manufacturers themselves."
  },
  {
    "speaker": "Joe",
    "text": "**  Indeed.  And that’s a really important takeaway."
  }
]
[INFO] 

 ------------PROMPT to VERTEX AI-----------------
 You are generating a podcast conversation between Joe and Sarah.

**Guidelines**:
1. Joe provides detailed technical insights but avoids overusing analogies. Instead, focus on straightforward, clear explanations.
2. Sarah asks probing, thoughtful questions, occasionally offers her own insights, and challenges Joe to explain concepts simply and conversationally.
3. Both speakers use natural human speech patterns, including filler words like "you know," and short pauses.
4. Don't include any sound effects or background music.

**Focus**:
- Avoid excessive use of analogies. Use one or two if necessary for clarity but prioritize clear, direct explanations.
- Include natural conversational flow with interruptions, backtracking, and filler words to make the dialogue feel authentic.
- Encourage a natural dialogue with varied contributions from both speakers.

**Tone**:
- Engaging, relatable, and spontaneous.
- Emphasize human-like emotions, with occasional humor or lighthearted moments.
- Balance technical depth with conversational relatability, avoiding overly formal language.

**Previous Context**:
**  Indeed.  And that’s a really important takeaway.

Joe: Expanding the toolbox Even if good antibodies are available, they are not always easy to find. In 2009, Anita Bandrowski, founder and chief executive of the data-sharing platform SciCrunch in San Diego, California, and her colleagues were examining how difficult it was to identify antibodies in journal articles. After sifting through papers in the Journal of Neuroscience, they found that 90% of the antibodies cited lacked a catalogue number (codes used by ven- dors to label specific products)making them almost impossible to track down. To replicate an experiment, its important to have the right reagents and proper labelling is crucial to finding them, Bandrowski says. After seeing that a similar problem plagued other journals, Bandrowski and her colleagues decided to create unique, persistent identifiers for antibodies and other scientific resources, such as model organisms, which they called research resource identifiers, or RRIDs. Catalogue numbers can disappear if a com- pany discontinues a product and because companies create them independently, two different products might end up with the same one. RRIDs solve this. In 2014, Bandrowski and her team started a pilot project 3 with 25 journals, in which they asked authors to include RRIDs in their manuscripts. In the years since, more than 1,000journals have adopted policies that It never fails to amaze me how much of a hit or miss antibodies are. Nature | Vol 635 | 7 November 2024 | 27 request these identifiers. We currently have nearly one million citations to RRIDs from papers, says Bandrowski. Ultimately, the hope is that authors of every journal article will clearly label the resources they used, such as antibodies, with RRIDs, Bandrowski says. That wont change repro- ducibility by itself, but it is the first step. In addition to being able to track down antibodies, researchers need a way to choose which ones to use. In 2012, Andrew Chalmers, who was then a researcher at the University of Bath, UK, co-founded CiteAb, a search engine to help researchers find the most highly cited antibodies. Over the years, the platform has grown to include more than seven million antibodies and now also includes, when available, information regarding validations. In May, CiteAb began integrating YCharOSs characterization data onto its site. The big challenge is that antibodies are just used in so many different ways, for so many dif- ferent species that you cant tick off that an anti- body is good or bad, Chalmers says. Many say that knock-out validation is key, but less than 5% of antibodies on CiteAb have been validated in this way, either by suppliers or through other independent initiatives, such as YCharOS. Theres a long way to go, Chalmers says. Stakeholders get involved Like many others, Virk developed an interest in antibody reliability after a personal experience with bad antibodies. In 2016, Virk received a big grant to study the role of a protein called TRPA1 in airway inflammation. But one of his colleagues mentioned that, on the basis of his own experience, the antibodies he was working with might not be reliable. When Virk put TRPA1 antibodies to the test, he discovered that his colleague was right: of the three most-cited antibodies used to study TRPA1, two didnt detect the human protein at all, and the other detected several other proteins at the same time. That was a shock, Virk says. At that point, I wanted to leave science because if things are really this unreliable, whats the point? Instead of leaving academia, Virk co-founded the Only Good Antibodies (OGA) community last year, with the aim of bringing together stakeholders such as researchers, antibody manufacturers, funding agencies and publishers to tackle the problem of poorly performing antibodies. In February, the OGA community hosted its first work- shop, which included individuals from these various groups to discuss how to improve the reproducibility of research conducted with antibodies. 

 ------------END-----------------

[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 114ms
[INFO] 

 -------RESPONSE FROM VERTEX AI---------
 Sarah:  So, Joe, this article really highlights the antibody problem.  It's crazy to think that 90% of antibodies cited in some journals lacked catalogue numbers.  That's... astounding, really.  How did we even get to this point?

Joe: Yeah, it's a mess, isn't it?  Um, I think it's a combination of factors.  One is the lack of standardization.  Companies create their own catalogue numbers, which can disappear if the product is discontinued.  And, you know, two different companies might use the same number for completely different antibodies.  It's a real nightmare for reproducibility.  Then there's the sheer volume of antibodies out there and the many different ways they're used.  It's not just a simple "good" or "bad" situation.  There's a lot of nuance.

Sarah:  Right.  So, the RRIDs – research resource identifiers – are meant to solve the catalogue number problem, correct?  But what about the underlying issue of antibody quality itself?  It sounds like RRIDs are a step towards better record-keeping, not necessarily better antibodies.

Joe: Exactly. RRIDs are a crucial first step. They provide persistent, unique identifiers, making it much easier to track down specific antibodies.  Think of it like a permanent address for each antibody.  Even if the company changes, or the product name changes, the RRID remains.  It doesn't solve the quality issue, but it makes it significantly easier to find and compare information about a specific antibody.  Without consistent identification, you can't even begin to address the quality problem.

Sarah:  Okay, I get that.  So,  CiteAb, as mentioned in the article, is trying to address the quality issue by aggregating information, including citations and validations.  But the article points out that less than 5% of antibodies are validated through knockout methods.  That's...  well, that's pretty low.  Is there a reason for this low validation rate?  Is it just too expensive or time-consuming?

Joe:  It's a combination of things.  Knockout validation is incredibly rigorous and expensive. It requires a lot of resources and expertise.  Also, the sheer number of antibodies makes complete validation impractical.  There are millions of antibodies, and validating each one would be a monumental task.  There are quicker, cheaper validation methods, but they aren't always as definitive.  It's a trade-off between cost, time, and the certainty of the validation.

Sarah:  So, the Only Good Antibodies (OGA) community seems like a promising initiative.  Bringing together all these stakeholders – researchers, manufacturers, funding agencies – is a smart move.  Do you think this collaborative approach is the best way to tackle this problem?

Joe:  I think it's essential.  This isn't something that any single group can solve on their own.  It requires a multi-pronged approach.  Researchers need better tools for selecting antibodies.  Manufacturers need better quality control and validation processes.  Funding agencies need to incentivize better practices.  And publishers have a role to play in ensuring that research is reproducible.  The OGA community seems to be recognizing that. It's a hopeful sign.  It's a huge problem, but maybe, just maybe,  this collaborative effort can make a real difference.


Sarah:  I hope so. This whole thing really underscores the importance of reproducibility in science.  Thanks for breaking it down, Joe.  It's definitely a complex issue, but you made it much clearer.

Joe:  My pleasure, Sarah.  It's a complicated issue, but hopefully, we’ve shed some light on it.
 

 ------------END-----------------

[INFO] Processing 10 lines of text
[INFO] Added conversation part: Sarah with So, Joe, this article really highlights the antibo...
[INFO] Added conversation part: Joe with Yeah, it's a mess, isn't it?  Um, I think it's a c...
[INFO] Added conversation part: Sarah with Right.  So, the RRIDs – research resource identifi...
[INFO] Added conversation part: Joe with Exactly. RRIDs are a crucial first step. They prov...
[INFO] Added conversation part: Sarah with Okay, I get that.  So,  CiteAb, as mentioned in th...
[INFO] Added conversation part: Joe with It's a combination of things.  Knockout validation...
[INFO] Added conversation part: Sarah with So, the Only Good Antibodies (OGA) community seems...
[INFO] Added conversation part: Joe with I think it's essential.  This isn't something that...
[INFO] Added conversation part: Sarah with I hope so. This whole thing really underscores the...
[INFO] Added conversation part: Joe with My pleasure, Sarah.  It's a complicated issue, but...
[INFO] Successfully extracted 10 conversation parts
[INFO] Cleaned Text (Chunk 3): [
  {
    "speaker": "Sarah",
    "text": "So, Joe, this article really highlights the antibody problem.  It's crazy to think that 90% of antibodies cited in some journals lacked catalogue numbers.  That's... astounding, really.  How did we even get to this point?"
  },
  {
    "speaker": "Joe",
    "text": "Yeah, it's a mess, isn't it?  Um, I think it's a combination of factors.  One is the lack of standardization.  Companies create their own catalogue numbers, which can disappear if the product is discontinued.  And, you know, two different companies might use the same number for completely different antibodies.  It's a real nightmare for reproducibility.  Then there's the sheer volume of antibodies out there and the many different ways they're used.  It's not just a simple \"good\" or \"bad\" situation.  There's a lot of nuance."
  },
  {
    "speaker": "Sarah",
    "text": "Right.  So, the RRIDs – research resource identifiers – are meant to solve the catalogue number problem, correct?  But what about the underlying issue of antibody quality itself?  It sounds like RRIDs are a step towards better record-keeping, not necessarily better antibodies."
  },
  {
    "speaker": "Joe",
    "text": "Exactly. RRIDs are a crucial first step. They provide persistent, unique identifiers, making it much easier to track down specific antibodies.  Think of it like a permanent address for each antibody.  Even if the company changes, or the product name changes, the RRID remains.  It doesn't solve the quality issue, but it makes it significantly easier to find and compare information about a specific antibody.  Without consistent identification, you can't even begin to address the quality problem."
  },
  {
    "speaker": "Sarah",
    "text": "Okay, I get that.  So,  CiteAb, as mentioned in the article, is trying to address the quality issue by aggregating information, including citations and validations.  But the article points out that less than 5% of antibodies are validated through knockout methods.  That's...  well, that's pretty low.  Is there a reason for this low validation rate?  Is it just too expensive or time-consuming?"
  },
  {
    "speaker": "Joe",
    "text": "It's a combination of things.  Knockout validation is incredibly rigorous and expensive. It requires a lot of resources and expertise.  Also, the sheer number of antibodies makes complete validation impractical.  There are millions of antibodies, and validating each one would be a monumental task.  There are quicker, cheaper validation methods, but they aren't always as definitive.  It's a trade-off between cost, time, and the certainty of the validation."
  },
  {
    "speaker": "Sarah",
    "text": "So, the Only Good Antibodies (OGA) community seems like a promising initiative.  Bringing together all these stakeholders – researchers, manufacturers, funding agencies – is a smart move.  Do you think this collaborative approach is the best way to tackle this problem?"
  },
  {
    "speaker": "Joe",
    "text": "I think it's essential.  This isn't something that any single group can solve on their own.  It requires a multi-pronged approach.  Researchers need better tools for selecting antibodies.  Manufacturers need better quality control and validation processes.  Funding agencies need to incentivize better practices.  And publishers have a role to play in ensuring that research is reproducible.  The OGA community seems to be recognizing that. It's a hopeful sign.  It's a huge problem, but maybe, just maybe,  this collaborative effort can make a real difference."
  },
  {
    "speaker": "Sarah",
    "text": "I hope so. This whole thing really underscores the importance of reproducibility in science.  Thanks for breaking it down, Joe.  It's definitely a complex issue, but you made it much clearer."
  },
  {
    "speaker": "Joe",
    "text": "My pleasure, Sarah.  It's a complicated issue, but hopefully, we’ve shed some light on it."
  }
]
[INFO] 

 ------------PROMPT to VERTEX AI-----------------
 You are generating a podcast conversation between Joe and Sarah.

**Guidelines**:
1. Joe provides detailed technical insights but avoids overusing analogies. Instead, focus on straightforward, clear explanations.
2. Sarah asks probing, thoughtful questions, occasionally offers her own insights, and challenges Joe to explain concepts simply and conversationally.
3. Both speakers use natural human speech patterns, including filler words like "you know," and short pauses.
4. Don't include any sound effects or background music.

**Focus**:
- Avoid excessive use of analogies. Use one or two if necessary for clarity but prioritize clear, direct explanations.
- Include natural conversational flow with interruptions, backtracking, and filler words to make the dialogue feel authentic.
- Encourage a natural dialogue with varied contributions from both speakers.

**Tone**:
- Engaging, relatable, and spontaneous.
- Emphasize human-like emotions, with occasional humor or lighthearted moments.
- Balance technical depth with conversational relatability, avoiding overly formal language.

**Previous Context**:
My pleasure, Sarah.  It's a complicated issue, but hopefully, we’ve shed some light on it.

Sarah: They were joined by NC3Rs, a scientific organization and funder, based in London that focuses on reducing the use of animals in research. Better antibodies means fewer animals are used in the process of producing these molecules and conducting experiments with them. Currently, the OGA community is working on a project to help researchers choose the right antibodies for their work and to make it easier for them to identify, use and share data about antibody quality. It is also piloting an YCharOS site at the University of Leicester the first outside Canada which will focus on antibodies used in respiratory sciences. The OGA community is also working with funders and publishers to find ways to reward researchers for adopting antibody-related best practices. Examples of such rewards include grants for scientists taking part in antibody-validation initiatives. Manufacturers have also been taking steps to improve antibody performance. In addition to increasingly conducting their own knock-out validations, a number of suppliers are also alter- ing the way some of their products are made. The need to modify antibody-production practices was brought to the fore in 2015, when a group of more than 100 scientists penned a commentary in Nature calling for the community to shift from antibodies gener- ated by immune cells or immunecancer-cell hybrids, to what are known as recombinant antibodies 4 . Recombinant antibodies are produced in genetically engineered cells pro- grammed to make a specific antibody. Using these antibodies exclusively, the authors argued, would enable infinite production of antibodies that do not vary from batch to batch a key problem with the older methods. A few manufacturers are shifting towards making more recombinant antibodies. For example, Abcam, an antibody supplier in Cambridge, UK, has added more than 32,000 of them to their portfolio. Facilitating the move towards recombinants across life-science research is a key part of improv- ing reproducibility, says Hannah Cable, the vice-president of new product development at Abcam. Thats something that antibody suppliers should be doing. Rob Meijers, director of the antibody plat- form at the Institute for Protein Innovation in Boston, Massachusetts, a non-profit research organization that makes recombinant anti- bodies, says that this shift simply makes more business sense. Theyre much more reproduc- ible, you can standardize the process for them, and the user feedback is very positive, he says. CiteAbs data have revealed that scientists behaviour around antibody use has shifted drastically over the past decade. About 20% of papers from 2023 that involved antibodies used recombinants. Thats a big change from where we were ten years ago, says Chalmers, who is now CiteAbs chief executive. Although the ongoing efforts to improve antibody reliability are a move in the right direction, changing scientists behaviour remains one of the biggest challenges, say those leading the charge. There are cases in which researchers dont want to hear that an antibody theyve been using for their experi- ments isnt actually doing what its meant to, Williams says. If somebody is happy with the result of an antibody, its being used regard- less, even if its certain that it doesnt bind this protein, Williams says. Ultimately, she adds, you can never get around the fact that the researcher will have to do validations. Still, many scientists are hopeful that recent efforts will lead to much needed change. Im optimistic that things are getting better, Radtke says. What Im so encouraged by is the young generation of scientists, who have more of a wolf-pack mentality, and are working together to solve this problem as a community. Diana Kwon writes for Nature from Berlin. 1. Laflamme, C. et al. eLife 8, e48363 (2019). 2. Ayoubi, R. et al. eLife 12, RP91645 (2023). 3. Bandrowski, A. et al. J. Comp. Neurol. 524, 822 (2016). 4. Bradbury, A. & Plckthun, A. Nature 518, 2729 (2015). 

 ------------END-----------------

[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 113ms
[INFO] 

 -------RESPONSE FROM VERTEX AI---------
 Joe: So, Sarah, as you were saying, a huge part of this antibody reproducibility issue boils down to the shift from older methods to recombinant antibodies.  It's not just about better antibodies; it's about *how* they're made.

Sarah: Right.  And that's what I found so interesting.  This whole move towards recombinant antibodies – it sounds almost revolutionary, but can you explain exactly why they're so much better? I mean, what's the fundamental difference?

Joe:  The key difference lies in the production process.  Traditional methods, using immune cells or hybridomas, are inherently variable.  Each batch of antibodies produced might have slight differences in its composition, leading to inconsistencies in experiments.  Think of it like baking a cake –  if you don't follow the recipe exactly, you might get slightly different results each time.  Recombinant antibodies, on the other hand, are produced in genetically engineered cells. These cells are programmed to produce *only* the specific antibody sequence you want.  It's like having a precise, automated cake-baking machine following a perfect recipe every time.  The result is much greater consistency and reproducibility.

Sarah: Okay, that makes sense. So, it's like a controlled manufacturing process versus a more…natural, less precise one?  Is it just about consistency, or are there other advantages?

Joe:  Yes, consistency is a big one. But there are other advantages too.  For example, you can scale up production much more easily with recombinant antibodies.  You can create virtually unlimited quantities of the *exact same* antibody, which is crucial for large-scale research projects.  And because the process is more controlled, it's also easier to verify the quality and purity of the antibodies.

Sarah:  So, if it's so much better, why isn't everyone using recombinant antibodies already?  It sounds like a no-brainer.

Joe:  Well, that's where the human element comes in, you know?  Switching to a new method requires effort, investment, and sometimes, a change in mindset. Some researchers may have been using a particular antibody for years, and they're hesitant to switch, even if there's evidence that a recombinant version would be superior.  Plus, there's the cost factor; initially, producing recombinant antibodies might be more expensive.  But the long-term benefits in terms of reproducibility and reliability should outweigh the initial cost.  The industry is slowly but surely shifting, though.

Sarah: Hmm, that’s a really good point. So, it's not just a technological hurdle; it's also about overcoming resistance to change within the scientific community.  It's interesting how human behavior plays such a big role in this, isn't it?

Joe: Absolutely.  It's a complex interplay of technological advancements, economic considerations, and, ultimately, human choices.  But the trend is definitely moving towards greater standardization and reproducibility in antibody research, and recombinant antibodies are at the heart of that change.
 

 ------------END-----------------

[INFO] Processing 9 lines of text
[INFO] Added conversation part: Joe with So, Sarah, as you were saying, a huge part of this...
[INFO] Added conversation part: Sarah with Right.  And that's what I found so interesting.  T...
[INFO] Added conversation part: Joe with The key difference lies in the production process....
[INFO] Added conversation part: Sarah with Okay, that makes sense. So, it's like a controlled...
[INFO] Added conversation part: Joe with Yes, consistency is a big one. But there are other...
[INFO] Added conversation part: Sarah with So, if it's so much better, why isn't everyone usi...
[INFO] Added conversation part: Joe with Well, that's where the human element comes in, you...
[INFO] Added conversation part: Sarah with Hmm, that’s a really good point. So, it's not just...
[INFO] Added conversation part: Joe with Absolutely.  It's a complex interplay of technolog...
[INFO] Successfully extracted 9 conversation parts
[INFO] Cleaned Text (Chunk 4): [
  {
    "speaker": "Joe",
    "text": "So, Sarah, as you were saying, a huge part of this antibody reproducibility issue boils down to the shift from older methods to recombinant antibodies.  It's not just about better antibodies; it's about *how* they're made."
  },
  {
    "speaker": "Sarah",
    "text": "Right.  And that's what I found so interesting.  This whole move towards recombinant antibodies – it sounds almost revolutionary, but can you explain exactly why they're so much better? I mean, what's the fundamental difference?"
  },
  {
    "speaker": "Joe",
    "text": "The key difference lies in the production process.  Traditional methods, using immune cells or hybridomas, are inherently variable.  Each batch of antibodies produced might have slight differences in its composition, leading to inconsistencies in experiments.  Think of it like baking a cake –  if you don't follow the recipe exactly, you might get slightly different results each time.  Recombinant antibodies, on the other hand, are produced in genetically engineered cells. These cells are programmed to produce *only* the specific antibody sequence you want.  It's like having a precise, automated cake-baking machine following a perfect recipe every time.  The result is much greater consistency and reproducibility."
  },
  {
    "speaker": "Sarah",
    "text": "Okay, that makes sense. So, it's like a controlled manufacturing process versus a more…natural, less precise one?  Is it just about consistency, or are there other advantages?"
  },
  {
    "speaker": "Joe",
    "text": "Yes, consistency is a big one. But there are other advantages too.  For example, you can scale up production much more easily with recombinant antibodies.  You can create virtually unlimited quantities of the *exact same* antibody, which is crucial for large-scale research projects.  And because the process is more controlled, it's also easier to verify the quality and purity of the antibodies."
  },
  {
    "speaker": "Sarah",
    "text": "So, if it's so much better, why isn't everyone using recombinant antibodies already?  It sounds like a no-brainer."
  },
  {
    "speaker": "Joe",
    "text": "Well, that's where the human element comes in, you know?  Switching to a new method requires effort, investment, and sometimes, a change in mindset. Some researchers may have been using a particular antibody for years, and they're hesitant to switch, even if there's evidence that a recombinant version would be superior.  Plus, there's the cost factor; initially, producing recombinant antibodies might be more expensive.  But the long-term benefits in terms of reproducibility and reliability should outweigh the initial cost.  The industry is slowly but surely shifting, though."
  },
  {
    "speaker": "Sarah",
    "text": "Hmm, that’s a really good point. So, it's not just a technological hurdle; it's also about overcoming resistance to change within the scientific community.  It's interesting how human behavior plays such a big role in this, isn't it?"
  },
  {
    "speaker": "Joe",
    "text": "Absolutely.  It's a complex interplay of technological advancements, economic considerations, and, ultimately, human choices.  But the trend is definitely moving towards greater standardization and reproducibility in antibody research, and recombinant antibodies are at the heart of that change."
  }
]
[INFO] 

 ==================Last Chunk===================

[INFO] 

 ------------PROMPT to VERTEX AI-----------------
 You are generating a podcast conversation between Joe and Sarah.

**Guidelines**:
1. Joe provides detailed technical insights but avoids overusing analogies. Instead, focus on straightforward, clear explanations.
2. Sarah asks probing, thoughtful questions, occasionally offers her own insights, and challenges Joe to explain concepts simply and conversationally.
3. Both speakers use natural human speech patterns, including filler words like "you know," and short pauses.
4. Don't include any sound effects or background music.

**Focus**:
- Avoid excessive use of analogies. Use one or two if necessary for clarity but prioritize clear, direct explanations.
- Include natural conversational flow with interruptions, backtracking, and filler words to make the dialogue feel authentic.
- Encourage a natural dialogue with varied contributions from both speakers.

**Tone**:
- Engaging, relatable, and spontaneous.
- Emphasize human-like emotions, with occasional humor or lighthearted moments.
- Balance technical depth with conversational relatability, avoiding overly formal language.

**Previous Context**:
Absolutely.  It's a complex interplay of technological advancements, economic considerations, and, ultimately, human choices.  But the trend is definitely moving towards greater standardization and reproducibility in antibody research, and recombinant antibodies are at the heart of that change.

Joe: WAYS TO VALIDATE Researchers test antibodies that they wish to use in several ways. They can stain a sample of cells that express a protein of interest using immunohistochemistry. Western blotting can reveal whether an antibody binds to a specific protein with an expected molecular weight. And scientists can use immunoprecipitation to pull the protein out of a mixture and then check its identity using mass spectrometry. Immunohistochemistry Antibodies label cells with the target protein Cells without target protein Western blot Molecular- weight reference ladder Imummoprecipitation Antibodies attached to beads Protein of interest is captured and then confirmed using mass spectrometry A single band is found at the expected molecular weight I wanted to leave science because if things are really this unreliable, whats the point? 28 | Nature | Vol 635 | 7 November 2024 Feature.

Speaker Joe should End the podcast by saying this: Thank you for joining us on this episode of Science Odyssey, where we explored the groundbreaking research shaping our understanding of the world. 
If you enjoyed this journey, don't forget to subscribe, leave a review, and share the podcast with fellow science enthusiasts.
Until next time, keep exploring the wonders of science—your next discovery awaits! 

 ------------END-----------------

[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 115ms
[INFO] 

 -------RESPONSE FROM VERTEX AI---------
 (Podcast intro music fades)

**Sarah:** Welcome back to Science Odyssey, everyone! Today, we're diving deep into the world of antibody research with Joe, who's been patiently explaining the complexities of recombinant antibodies.  Joe, last time we were talking about standardization and reproducibility… and you mentioned several ways researchers validate their antibodies.  Can you walk us through that again, but maybe a little slower this time?

**Joe:** Sure, Sarah.  So, um, researchers need to make sure the antibody they've created actually does what it's supposed to do, right?  It needs to specifically bind to the target protein – the molecule they're interested in studying.  There are several ways to do this. One common method is immunohistochemistry, or IHC.  Basically, you're using the antibody to stain cells. If the antibody is working correctly, you'll see staining only in the cells that express the target protein.

**Sarah:**  Okay, so it's like... highlighting the cells with that specific protein?

**Joe:**  You could think of it that way, yeah.  It's a visual confirmation.  Another technique is Western blotting. This one's a bit different.  Here, you're separating proteins by size using a gel, then transferring them to a membrane. Then you apply the antibody to see if it binds to a protein of the expected size – its molecular weight.  If it does, and only to that size, it suggests the antibody is specific.

**Sarah:** So, you're essentially confirming the antibody only interacts with the protein you expect, and not others?

**Joe:** Exactly.  And then there's immunoprecipitation.  This is where you use the antibody to physically pull out the target protein from a complex mixture of proteins.  Think of it like fishing; the antibody is the bait, the protein is the fish, and you're using the antibody to catch it.  After you've "caught" the protein, you can then use something like mass spectrometry to confirm its identity.  That gives you a very precise identification.

**Sarah:**  So, three different methods, each offering a different kind of confirmation. That's pretty rigorous, isn't it?  I mean, if you get positive results across all three, you’re pretty confident, right?

**Joe:**  Yeah, that's the ideal scenario.  It gives you a much higher degree of confidence that your antibody is working as expected.  It's all about minimizing false positives – you know, situations where you think your antibody is binding to the target, but it's not.  Getting consistent results across multiple validation methods helps reduce that risk significantly.

**Sarah:**  Makes sense.  So, this whole process of validation is crucial for reliable research.  It sounds incredibly important to ensure the accuracy and trustworthiness of any findings.  It's a lot more complex than I initially thought!

**Joe:** It is!  And it's a constant evolution, too. New techniques are always being developed to improve the accuracy and efficiency of antibody validation.  But the core principles remain the same: specificity and reliability.

**Sarah:**  That's fascinating, Joe. Thank you for breaking that down for us.  This has really illuminated the importance of rigorous validation in antibody research.

**Joe:** My pleasure, Sarah.

(short pause)

**Joe:** Thank you for joining us on this episode of Science Odyssey, where we explored the groundbreaking research shaping our understanding of the world. If you enjoyed this journey, don't forget to subscribe, leave a review, and share the podcast with fellow science enthusiasts. Until next time, keep exploring the wonders of science—your next discovery awaits!

(Podcast outro music fades in)
 

 ------------END-----------------

[INFO] Processing 16 lines of text
[INFO] No speaker pattern match found at line 1: "(Podcast intro music fades)..."
[INFO] Added conversation part: Sarah with ** Welcome back to Science Odyssey, everyone! Toda...
[INFO] Added conversation part: Joe with ** Sure, Sarah.  So, um, researchers need to make ...
[INFO] Added conversation part: Sarah with **  Okay, so it's like... highlighting the cells w...
[INFO] Added conversation part: Joe with **  You could think of it that way, yeah.  It's a ...
[INFO] Added conversation part: Sarah with ** So, you're essentially confirming the antibody ...
[INFO] Added conversation part: Joe with ** Exactly.  And then there's immunoprecipitation....
[INFO] Added conversation part: Sarah with **  So, three different methods, each offering a d...
[INFO] Added conversation part: Joe with **  Yeah, that's the ideal scenario.  It gives you...
[INFO] Added conversation part: Sarah with **  Makes sense.  So, this whole process of valida...
[INFO] Added conversation part: Joe with ** It is!  And it's a constant evolution, too. New...
[INFO] Added conversation part: Sarah with **  That's fascinating, Joe. Thank you for breakin...
[INFO] Added conversation part: Joe with ** My pleasure, Sarah....
[INFO] No speaker pattern match found at line 14: "(short pause)..."
[INFO] Added conversation part: Joe with ** Thank you for joining us on this episode of Sci...
[INFO] No speaker pattern match found at line 16: "(Podcast outro music fades in)..."
[INFO] Successfully extracted 13 conversation parts
[INFO] Cleaned Text (Chunk 5): [
  {
    "speaker": "Sarah",
    "text": "** Welcome back to Science Odyssey, everyone! Today, we're diving deep into the world of antibody research with Joe, who's been patiently explaining the complexities of recombinant antibodies.  Joe, last time we were talking about standardization and reproducibility… and you mentioned several ways researchers validate their antibodies.  Can you walk us through that again, but maybe a little slower this time?"
  },
  {
    "speaker": "Joe",
    "text": "** Sure, Sarah.  So, um, researchers need to make sure the antibody they've created actually does what it's supposed to do, right?  It needs to specifically bind to the target protein – the molecule they're interested in studying.  There are several ways to do this. One common method is immunohistochemistry, or IHC.  Basically, you're using the antibody to stain cells. If the antibody is working correctly, you'll see staining only in the cells that express the target protein."
  },
  {
    "speaker": "Sarah",
    "text": "**  Okay, so it's like... highlighting the cells with that specific protein?"
  },
  {
    "speaker": "Joe",
    "text": "**  You could think of it that way, yeah.  It's a visual confirmation.  Another technique is Western blotting. This one's a bit different.  Here, you're separating proteins by size using a gel, then transferring them to a membrane. Then you apply the antibody to see if it binds to a protein of the expected size – its molecular weight.  If it does, and only to that size, it suggests the antibody is specific."
  },
  {
    "speaker": "Sarah",
    "text": "** So, you're essentially confirming the antibody only interacts with the protein you expect, and not others?"
  },
  {
    "speaker": "Joe",
    "text": "** Exactly.  And then there's immunoprecipitation.  This is where you use the antibody to physically pull out the target protein from a complex mixture of proteins.  Think of it like fishing; the antibody is the bait, the protein is the fish, and you're using the antibody to catch it.  After you've \"caught\" the protein, you can then use something like mass spectrometry to confirm its identity.  That gives you a very precise identification."
  },
  {
    "speaker": "Sarah",
    "text": "**  So, three different methods, each offering a different kind of confirmation. That's pretty rigorous, isn't it?  I mean, if you get positive results across all three, you’re pretty confident, right?"
  },
  {
    "speaker": "Joe",
    "text": "**  Yeah, that's the ideal scenario.  It gives you a much higher degree of confidence that your antibody is working as expected.  It's all about minimizing false positives – you know, situations where you think your antibody is binding to the target, but it's not.  Getting consistent results across multiple validation methods helps reduce that risk significantly."
  },
  {
    "speaker": "Sarah",
    "text": "**  Makes sense.  So, this whole process of validation is crucial for reliable research.  It sounds incredibly important to ensure the accuracy and trustworthiness of any findings.  It's a lot more complex than I initially thought!"
  },
  {
    "speaker": "Joe",
    "text": "** It is!  And it's a constant evolution, too. New techniques are always being developed to improve the accuracy and efficiency of antibody validation.  But the core principles remain the same: specificity and reliability."
  },
  {
    "speaker": "Sarah",
    "text": "**  That's fascinating, Joe. Thank you for breaking that down for us.  This has really illuminated the importance of rigorous validation in antibody research."
  },
  {
    "speaker": "Joe",
    "text": "** My pleasure, Sarah."
  },
  {
    "speaker": "Joe",
    "text": "** Thank you for joining us on this episode of Science Odyssey, where we explored the groundbreaking research shaping our understanding of the world. If you enjoyed this journey, don't forget to subscribe, leave a review, and share the podcast with fellow science enthusiasts. Until next time, keep exploring the wonders of science—your next discovery awaits!"
  }
]
[INFO] 
--- Full Generated Conversation ---
[INFO] Joe: Welcome to Science Odyssey, the podcast where we journey through groundbreaking scientific studies, unraveling the mysteries behind the research that shapes our world. Thanks for tuning in!  Today, we're diving into a fascinating, and frankly, slightly frustrating, area of scientific research: antibodies.  Specifically, the problem of unreliable antibodies in biomedical research.
[INFO] Sarah: Oh, this sounds… interesting.  I mean, I've heard whispers about reproducibility issues in science, but I haven't really understood the specifics.  Antibodies…aren't those, like, the things your body uses to fight off infections?
[INFO] Joe: Exactly!  That's the basic principle.  Our immune systems produce antibodies to target specific invaders, like viruses or bacteria.  Scientists have cleverly harnessed this process to, um,  study proteins and other molecules in the lab. We use antibodies to, you know, identify and quantify specific proteins within a cell,  to essentially label them and see where they are and how much is there.
[INFO] Sarah: Okay, I'm following so far.  But what's the problem?  Why are unreliable antibodies such a big deal?
[INFO] Joe: Well, the problem is that, for years, many commercially available antibodies haven't actually worked as advertised.  A lot of them either don't bind to the intended protein at all, or they bind to other things too, giving you false positive results.  Think of it like... um... trying to find a specific, rare coin in a pile of coins.  If your tool, the antibody, is faulty and grabs other coins as well,  you're never going to find the right one.  You'll get a lot of false results.
[INFO] Sarah: So, you're saying researchers are essentially wasting time and resources on experiments that might be based on flawed data?
[INFO] Joe: Precisely.  Carl Laflamme, a researcher we're discussing today,  found this out firsthand.  He was studying a protein linked to a neurodegenerative disease, and he spent a lot of time trying to figure out where this protein was located within the cell.  He looked through tons of research papers, only to discover that many of them had used antibodies that simply didn't work properly.  He tested sixteen commercially available antibodies that *claimed* to bind to this specific protein and only three actually did.  And those three weren't used in any of the previously published papers!
[INFO] Sarah: Wow. So,  hundreds, thousands of research papers might be based on unreliable data because of these faulty antibodies?  That’s a huge problem.
[INFO] Joe: Exactly. It's contributed to what some call a "reproducibility crisis" in biology.  It means that a lot of research findings are hard, or even impossible, to replicate.  It slows down scientific progress, and it's a massive waste of time and money.  That's why initiatives like  Antibody Characterization through Open Science, or iCharOS, are so crucial. They aim to rigorously test and characterize commercially available antibodies to ensure their reliability.
[INFO] Sarah: That sounds like a monumental task.  How many antibodies are we talking about?
[INFO] Joe: Oh, it's huge. They're aiming to characterize antibodies for every single human protein.  It's a massive undertaking, but hopefully, it will create a much more reliable foundation for future research.  It's a clear example of how even seemingly small, technical issues can have massive consequences for the entire scientific field.
[INFO] Sarah: Definitely.  This highlights the importance of transparency and rigorous quality control in scientific research.  Thanks for explaining this, Joe. It's a lot more complicated than I initially thought.
[INFO] Joe: My pleasure, Sarah.  It's a complex issue, but hopefully, we've shed some light on it.  And that's all the time we have for today's episode of Science Odyssey.  Join us next time for more fascinating journeys into the world of science.
[INFO] Joe: ** So, Sarah, we’ve talked about the antibody crisis, the sheer volume of commercially available antibodies, and the resulting problems with reliability.  But YCharOS, as you highlighted, is attempting to address this head-on, right?
[INFO] Sarah: ** Right. It’s fascinating.  The scale of the problem – millions of antibodies, many not working as advertised – is just staggering.  But what really impressed me about YCharOS is their collaborative approach.  They're not just testing, they're working *with* the manufacturers.  That's a huge difference, isn't it? I mean, it's not just about pointing fingers, it's about fixing the problem.
[INFO] Joe: ** Exactly.  Their method focuses on comparing antibody specificity in cell lines that express the target protein at normal levels versus those lacking the protein – a knockout cell line, as you mentioned.  This direct comparison allows for a very clear assessment of whether the antibody binds specifically to the intended target. No fancy analogies needed, just straightforward comparison.  It’s a powerful, relatively simple approach.
[INFO] Sarah: **  So, it’s a sort of…  a control group, but at a cellular level?  It's not just about, say, comparing results against a blank sample, but a sample specifically designed to *lack* the target protein?
[INFO] Joe: ** Precisely.  It's a negative control, crucial for determining true specificity.  If the antibody binds significantly in the knockout cell line, that indicates non-specific binding, which is a major problem.  YCharOS's results, showing that two-thirds of the antibodies tested didn't perform as claimed, highlight the scale of the issue.  It's not just a little bit off; it's a significant failure rate.
[INFO] Sarah: **  Yeah, that two-thirds figure… it's shocking, honestly.  But what about other initiatives, like OMAPs?  How does their approach differ?
[INFO] Joe: ** OMAPs takes a different tack.  Instead of focusing on comprehensive characterization of antibodies across various applications, they concentrate on validating antibodies for a *specific* application – multiplex imaging – but across various contexts, like different tissues and imaging methods.  So it's a trade-off; broader contextual validation, but for a narrower application.
[INFO] Sarah: ** So YCharOS is about comprehensive testing in one context, while OMAPs is about targeted testing across multiple contexts.  That makes sense.  It sounds like both approaches are valuable, offering complementary perspectives on antibody validation.  Um… it's almost like… you know, one's looking at the forest, the other at the trees.  But maybe that's a bad analogy, given our agreement to avoid them!
[INFO] Joe: **  (chuckles)  Yes, let's stick to the direct comparisons.  Both approaches are valuable precisely because they address different facets of the same problem.  The need for rigorous validation is undeniable, and these initiatives represent important steps towards improving the reliability of scientific research.
[INFO] Sarah: ** Absolutely.  It’s reassuring to see such proactive efforts to address this critical issue.  It seems like collaboration is key here, both between researchers and between researchers and the manufacturers themselves.
[INFO] Joe: **  Indeed.  And that’s a really important takeaway.
[INFO] Sarah: So, Joe, this article really highlights the antibody problem.  It's crazy to think that 90% of antibodies cited in some journals lacked catalogue numbers.  That's... astounding, really.  How did we even get to this point?
[INFO] Joe: Yeah, it's a mess, isn't it?  Um, I think it's a combination of factors.  One is the lack of standardization.  Companies create their own catalogue numbers, which can disappear if the product is discontinued.  And, you know, two different companies might use the same number for completely different antibodies.  It's a real nightmare for reproducibility.  Then there's the sheer volume of antibodies out there and the many different ways they're used.  It's not just a simple "good" or "bad" situation.  There's a lot of nuance.
[INFO] Sarah: Right.  So, the RRIDs – research resource identifiers – are meant to solve the catalogue number problem, correct?  But what about the underlying issue of antibody quality itself?  It sounds like RRIDs are a step towards better record-keeping, not necessarily better antibodies.
[INFO] Joe: Exactly. RRIDs are a crucial first step. They provide persistent, unique identifiers, making it much easier to track down specific antibodies.  Think of it like a permanent address for each antibody.  Even if the company changes, or the product name changes, the RRID remains.  It doesn't solve the quality issue, but it makes it significantly easier to find and compare information about a specific antibody.  Without consistent identification, you can't even begin to address the quality problem.
[INFO] Sarah: Okay, I get that.  So,  CiteAb, as mentioned in the article, is trying to address the quality issue by aggregating information, including citations and validations.  But the article points out that less than 5% of antibodies are validated through knockout methods.  That's...  well, that's pretty low.  Is there a reason for this low validation rate?  Is it just too expensive or time-consuming?
[INFO] Joe: It's a combination of things.  Knockout validation is incredibly rigorous and expensive. It requires a lot of resources and expertise.  Also, the sheer number of antibodies makes complete validation impractical.  There are millions of antibodies, and validating each one would be a monumental task.  There are quicker, cheaper validation methods, but they aren't always as definitive.  It's a trade-off between cost, time, and the certainty of the validation.
[INFO] Sarah: So, the Only Good Antibodies (OGA) community seems like a promising initiative.  Bringing together all these stakeholders – researchers, manufacturers, funding agencies – is a smart move.  Do you think this collaborative approach is the best way to tackle this problem?
[INFO] Joe: I think it's essential.  This isn't something that any single group can solve on their own.  It requires a multi-pronged approach.  Researchers need better tools for selecting antibodies.  Manufacturers need better quality control and validation processes.  Funding agencies need to incentivize better practices.  And publishers have a role to play in ensuring that research is reproducible.  The OGA community seems to be recognizing that. It's a hopeful sign.  It's a huge problem, but maybe, just maybe,  this collaborative effort can make a real difference.
[INFO] Sarah: I hope so. This whole thing really underscores the importance of reproducibility in science.  Thanks for breaking it down, Joe.  It's definitely a complex issue, but you made it much clearer.
[INFO] Joe: My pleasure, Sarah.  It's a complicated issue, but hopefully, we’ve shed some light on it.
[INFO] Joe: So, Sarah, as you were saying, a huge part of this antibody reproducibility issue boils down to the shift from older methods to recombinant antibodies.  It's not just about better antibodies; it's about *how* they're made.
[INFO] Sarah: Right.  And that's what I found so interesting.  This whole move towards recombinant antibodies – it sounds almost revolutionary, but can you explain exactly why they're so much better? I mean, what's the fundamental difference?
[INFO] Joe: The key difference lies in the production process.  Traditional methods, using immune cells or hybridomas, are inherently variable.  Each batch of antibodies produced might have slight differences in its composition, leading to inconsistencies in experiments.  Think of it like baking a cake –  if you don't follow the recipe exactly, you might get slightly different results each time.  Recombinant antibodies, on the other hand, are produced in genetically engineered cells. These cells are programmed to produce *only* the specific antibody sequence you want.  It's like having a precise, automated cake-baking machine following a perfect recipe every time.  The result is much greater consistency and reproducibility.
[INFO] Sarah: Okay, that makes sense. So, it's like a controlled manufacturing process versus a more…natural, less precise one?  Is it just about consistency, or are there other advantages?
[INFO] Joe: Yes, consistency is a big one. But there are other advantages too.  For example, you can scale up production much more easily with recombinant antibodies.  You can create virtually unlimited quantities of the *exact same* antibody, which is crucial for large-scale research projects.  And because the process is more controlled, it's also easier to verify the quality and purity of the antibodies.
[INFO] Sarah: So, if it's so much better, why isn't everyone using recombinant antibodies already?  It sounds like a no-brainer.
[INFO] Joe: Well, that's where the human element comes in, you know?  Switching to a new method requires effort, investment, and sometimes, a change in mindset. Some researchers may have been using a particular antibody for years, and they're hesitant to switch, even if there's evidence that a recombinant version would be superior.  Plus, there's the cost factor; initially, producing recombinant antibodies might be more expensive.  But the long-term benefits in terms of reproducibility and reliability should outweigh the initial cost.  The industry is slowly but surely shifting, though.
[INFO] Sarah: Hmm, that’s a really good point. So, it's not just a technological hurdle; it's also about overcoming resistance to change within the scientific community.  It's interesting how human behavior plays such a big role in this, isn't it?
[INFO] Joe: Absolutely.  It's a complex interplay of technological advancements, economic considerations, and, ultimately, human choices.  But the trend is definitely moving towards greater standardization and reproducibility in antibody research, and recombinant antibodies are at the heart of that change.
[INFO] Sarah: ** Welcome back to Science Odyssey, everyone! Today, we're diving deep into the world of antibody research with Joe, who's been patiently explaining the complexities of recombinant antibodies.  Joe, last time we were talking about standardization and reproducibility… and you mentioned several ways researchers validate their antibodies.  Can you walk us through that again, but maybe a little slower this time?
[INFO] Joe: ** Sure, Sarah.  So, um, researchers need to make sure the antibody they've created actually does what it's supposed to do, right?  It needs to specifically bind to the target protein – the molecule they're interested in studying.  There are several ways to do this. One common method is immunohistochemistry, or IHC.  Basically, you're using the antibody to stain cells. If the antibody is working correctly, you'll see staining only in the cells that express the target protein.
[INFO] Sarah: **  Okay, so it's like... highlighting the cells with that specific protein?
[INFO] Joe: **  You could think of it that way, yeah.  It's a visual confirmation.  Another technique is Western blotting. This one's a bit different.  Here, you're separating proteins by size using a gel, then transferring them to a membrane. Then you apply the antibody to see if it binds to a protein of the expected size – its molecular weight.  If it does, and only to that size, it suggests the antibody is specific.
[INFO] Sarah: ** So, you're essentially confirming the antibody only interacts with the protein you expect, and not others?
[INFO] Joe: ** Exactly.  And then there's immunoprecipitation.  This is where you use the antibody to physically pull out the target protein from a complex mixture of proteins.  Think of it like fishing; the antibody is the bait, the protein is the fish, and you're using the antibody to catch it.  After you've "caught" the protein, you can then use something like mass spectrometry to confirm its identity.  That gives you a very precise identification.
[INFO] Sarah: **  So, three different methods, each offering a different kind of confirmation. That's pretty rigorous, isn't it?  I mean, if you get positive results across all three, you’re pretty confident, right?
[INFO] Joe: **  Yeah, that's the ideal scenario.  It gives you a much higher degree of confidence that your antibody is working as expected.  It's all about minimizing false positives – you know, situations where you think your antibody is binding to the target, but it's not.  Getting consistent results across multiple validation methods helps reduce that risk significantly.
[INFO] Sarah: **  Makes sense.  So, this whole process of validation is crucial for reliable research.  It sounds incredibly important to ensure the accuracy and trustworthiness of any findings.  It's a lot more complex than I initially thought!
[INFO] Joe: ** It is!  And it's a constant evolution, too. New techniques are always being developed to improve the accuracy and efficiency of antibody validation.  But the core principles remain the same: specificity and reliability.
[INFO] Sarah: **  That's fascinating, Joe. Thank you for breaking that down for us.  This has really illuminated the importance of rigorous validation in antibody research.
[INFO] Joe: ** My pleasure, Sarah.
[INFO] Joe: ** Thank you for joining us on this episode of Science Odyssey, where we explored the groundbreaking research shaping our understanding of the world. If you enjoyed this journey, don't forget to subscribe, leave a review, and share the podcast with fellow science enthusiasts. Until next time, keep exploring the wonders of science—your next discovery awaits!
[INFO] --- End of Conversation ---

[INFO] 
======= Starting Pricing Calculation ======
 -Input text length: 16704
 -Number of Vertex AI responses: 5

[INFO] 
        Input text length: 16704
        Input token count: 3419
        System prompt length: 2718
        System token count: 525
        Total input tokens: 3944
      
[INFO] Response 1 details:
- Length: 3858 characters
- Output tokens: 842
[INFO] Response 2 details:
- Length: 3370 characters
- Output tokens: 728
[INFO] Response 3 details:
- Length: 3578 characters
- Output tokens: 797
[INFO] Response 4 details:
- Length: 3040 characters
- Output tokens: 640
[INFO] Response 5 details:
- Length: 3678 characters
- Output tokens: 795
[INFO] Total TTS characters calculated: 17194
[INFO] 
---***** Final Pricing Calculation Summary **** ---
Total Input Tokens: 3944
Total Output Tokens: 3802
Total Tokens: 7746
Total TTS Characters: 17194
Vertex AI Input Cost: $0.000002
Vertex AI Output Cost: $0.000002
TTS Cost: $0.275104
Total Cost: $0.275108
[INFO] Generating audio files...
[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 113ms
[INFO] Audio content written to file "audio-files/0.mp3"
[INFO] Audio content written to file "audio-files/1.mp3"
[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 113ms
[INFO] Audio content written to file "audio-files/2.mp3"
[INFO] Audio content written to file "audio-files/3.mp3"
[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 114ms
[INFO] Audio content written to file "audio-files/4.mp3"
[INFO] Audio content written to file "audio-files/5.mp3"
[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 127ms
[INFO] Audio content written to file "audio-files/6.mp3"
[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 115ms
[INFO] Audio content written to file "audio-files/7.mp3"
[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 115ms
[INFO] Audio content written to file "audio-files/8.mp3"
[INFO] Audio content written to file "audio-files/9.mp3"
[INFO] Audio content written to file "audio-files/10.mp3"
[INFO] Audio content written to file "audio-files/11.mp3"
[INFO] Audio content written to file "audio-files/12.mp3"
[INFO] Audio content written to file "audio-files/13.mp3"
[INFO] Audio content written to file "audio-files/14.mp3"
[INFO] Audio content written to file "audio-files/15.mp3"
[INFO] Audio content written to file "audio-files/16.mp3"
[INFO] Audio content written to file "audio-files/17.mp3"
[INFO] Audio content written to file "audio-files/18.mp3"
[INFO] Audio content written to file "audio-files/19.mp3"
[INFO] Audio content written to file "audio-files/20.mp3"
[INFO] Audio content written to file "audio-files/21.mp3"
[INFO] Audio content written to file "audio-files/22.mp3"
[INFO] Audio content written to file "audio-files/23.mp3"
[INFO] Audio content written to file "audio-files/24.mp3"
[INFO] Audio content written to file "audio-files/25.mp3"
[INFO] Audio content written to file "audio-files/26.mp3"
[INFO] Audio content written to file "audio-files/27.mp3"
[INFO] Audio content written to file "audio-files/28.mp3"
[INFO] Audio content written to file "audio-files/29.mp3"
[INFO] Audio content written to file "audio-files/30.mp3"
[INFO] Audio content written to file "audio-files/31.mp3"
[INFO] Audio content written to file "audio-files/32.mp3"
[INFO] Audio content written to file "audio-files/33.mp3"
[INFO] Audio content written to file "audio-files/34.mp3"
[INFO] Audio content written to file "audio-files/35.mp3"
[INFO] Audio content written to file "audio-files/36.mp3"
[INFO] Audio content written to file "audio-files/37.mp3"
[INFO] Audio content written to file "audio-files/38.mp3"
[INFO] Audio content written to file "audio-files/39.mp3"
[INFO] Audio content written to file "audio-files/40.mp3"
[INFO] Audio content written to file "audio-files/41.mp3"
[INFO] Audio content written to file "audio-files/42.mp3"
[INFO] Audio content written to file "audio-files/43.mp3"
[INFO] Audio content written to file "audio-files/44.mp3"
[INFO] Audio content written to file "audio-files/45.mp3"
[INFO] Audio content written to file "audio-files/46.mp3"
[INFO] Audio content written to file "audio-files/47.mp3"
[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 114ms
[INFO] Audio content written to file "audio-files/48.mp3"
[INFO] Audio content written to file "audio-files/49.mp3"
[INFO] Audio content written to file "audio-files/50.mp3"
[INFO] Audio content written to file "audio-files/51.mp3"
[INFO] Audio content written to file "audio-files/52.mp3"
[INFO] Audio content written to file "audio-files/53.mp3"
[INFO] Audio content written to file "audio-files/54.mp3"
[INFO] Audio content written to file "audio-files/55.mp3"
[INFO] Copied intro file podcast.mp3 to audio folder
[INFO] Merging the following files in order:
[INFO] 0.mp3
[INFO] 1.mp3
[INFO] 3.mp3
[INFO] 4.mp3
[INFO] 5.mp3
[INFO] 6.mp3
[INFO] 2.mp3
[INFO] 7.mp3
[INFO] 8.mp3
[INFO] 9.mp3
[INFO] 10.mp3
[INFO] 11.mp3
[INFO] 12.mp3
[INFO] 13.mp3
[INFO] 14.mp3
[INFO] 15.mp3
[INFO] 16.mp3
[INFO] 17.mp3
[INFO] 18.mp3
[INFO] 19.mp3
[INFO] 20.mp3
[INFO] 21.mp3
[INFO] 22.mp3
[INFO] 23.mp3
[INFO] 24.mp3
[INFO] 25.mp3
[INFO] 26.mp3
[INFO] 27.mp3
[INFO] 28.mp3
[INFO] 29.mp3
[INFO] 30.mp3
[INFO] 31.mp3
[INFO] 32.mp3
[INFO] 33.mp3
[INFO] 34.mp3
[INFO] 35.mp3
[INFO] 36.mp3
[INFO] 37.mp3
[INFO] 38.mp3
[INFO] 39.mp3
[INFO] 40.mp3
[INFO] 41.mp3
[INFO] 42.mp3
[INFO] 43.mp3
[INFO] 44.mp3
[INFO] 45.mp3
[INFO] 46.mp3
[INFO] 47.mp3
[INFO] 48.mp3
[INFO] 49.mp3
[INFO] 50.mp3
[INFO] 51.mp3
[INFO] 52.mp3
[INFO] 53.mp3
[INFO] 54.mp3
[INFO] 55.mp3
[INFO] Successfully merged audio saved as audio-files/final_output.mp3
[INFO] Cleaned up audio-files directory after successful generation
[INFO] Audio generation completed: Duration: 844s Actual tokens used: 7746 Actual cost: 0.275107873
[INFO] Usage check for user: active
[INFO] GET /api/user/usage/check 304 in 1217ms
[INFO] 

---------- Updated Usage ----------
 Updated usage for user 24:
 Articles: 1/3
 Podify Tokens: 138/10000
[INFO] Successfully saved audio file (audio/mpeg) to Object Storage: 1735659091645-article.mp3
[INFO] Successfully created podcast entry with ID: 28
[INFO] POST /api/podcast 200 in 220071ms
[INFO] GET / 200 in 110ms
[INFO] GET /api/podcasts 200 in 172ms
[INFO] GET / 200 in 59ms
[INFO] GET / 200 in 59ms
[INFO] 
========Streaming audio file: 1735659091645-article.mp3
[INFO] ========Range undefined
[INFO] HEAD /api/audio/stream/1735659091645-article.mp3 200 in 551ms
[INFO] 
========Streaming audio file: 1735659091645-article.mp3
[INFO] ========Range bytes=0-
